



# Rak v Sloveniji

## Cancer in Slovenia

2021

letno poročilo  
annual report

# Rak v Sloveniji

## Cancer in Slovenia

2020

## Naslov *Title*

Rak v Sloveniji 2020 / Cancer in Slovenia 2020

## Uredniški odbor *Editorial Board*

Vesna Zadnik, glavna urednica / editor-in-chief  
Gorana Gašljević, Marko Hočevar, Katja Jarm, Vera Pompe-Kirn,  
Primož Strojan, Sonja Tomšič, Branko Zakotnik in Tina Žagar

## Obdelava in analiza podatkov *Data Processing and Analysis*

Nika Bric, Tina Žagar, Katarina Lokar, Miran Mlakar in Mojca Birk

## Oblikovanje in priprava za tisk *Design and Typesetting*

Nika Bric

## Lektura *Copy editing*

Jezikovna zadruga Soglasnik / Soglasnik Language Cooperative

## Tisk *Printing*

TISK ŽNIDARIČ d.o.o.

## Izdajatelj *Published by*

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia  
Epidemiologija in register raka / Epidemiology and Cancer Registry  
Register raka Republike Slovenije / Slovenian Cancer Registry

## Naklada *Published in*

500 izvodov / 500 copies

## Nasvet za citiranje *Recommended Reference*

Rak v Sloveniji 2020. Ljubljana: Onkološki inštitut Ljubljana,  
Epidemiologija in register raka, Register raka Republike Slovenije, 2023.  
Cancer in Slovenia 2020. Ljubljana: Institute of Oncology Ljubljana,  
Epidemiology and Cancer Registry, Slovenian Cancer Registry, 2023.

## Osebe Registra raka Republike Slovenije *Staff of the Slovenian Cancer Registry*

Vesna Zadnik, vodja / head  
Agata Čampa, Vesna Drolec, Maruška Ferjančič, Katja Hribar, Andrej Kirn, Katja Kolenc  
Mokotar, Andrej Krašovec, Martina Omerzo, Branka Pestotnik, Sabina Prvinšek, Polona  
Rus, Darja Strle, Laura Šeneker Zupanc, Frančiška Škrlec, Polona Škulj, Urška Tomšič,  
Snežana Umičević, Boštjan Zavrtnik, Brigita Zore, Mojca Birk, Nika Bric, Ana Mihor, Miran  
Mlakar, Teja Oblak, Katarina Lokar, Sonja Tomšič, Katarina Torkar, Tina Žagar

## Naslov *Correspondence to*

Register raka Republike Slovenije / Slovenian Cancer Registry  
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana  
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija  
Telefon / Phone: + 386 1 5879 450  
E-pošta / E-mail: register@onko-i.si  
Spletna stran / Web site:  
<http://www.onko-i.si/rrs/> <http://www.slora.si/>  
<http://www.onko-i.si/eng/crs/> <http://www.slora.si/en/>

Uvodnik	6
<i>Editorial</i>	7
Podatki	8
Viri podatkov	8
Obdelava podatkov	9
Kakovost podatkov	10
<i>Data</i>	12
Data Sources	12
Data Processing	13
Data Quality	14
Rak v Sloveniji	15
Osnovni podatki o raku v Sloveniji 2020	16
Starost bolnikov	16
Časovni trend	16
Najpogostejši raki	18
Trend najpogostejših rakov	21
Redki raki	22
Preživetje	23
Primerjava z Evropo	26
<i>Cancer in Slovenia</i>	28
Basic figures on cancer in Slovenia 2020	28
Age of patients	28
Time trends	29
Most frequent cancers	29
Time trends for most frequent cancers	29
Rare cancers	30
Survival	30
Comparisons with Europe	31
Incidenca	32
Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2011–2020 in 2023.	32
Table 1: Observed and estimated cancer incidence by sex, Slovenia 2011–2020 and 2023.	32
Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka po spolu, Slovenija 2020.	33
Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2020.	33
Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2020.	34
Table 3: Cancer incidence by age and by sex with crude rate (GS) per 100,000 population and cumulative rate (KS), Slovenia 2020.	34

Tabela 4a:	Incidenca mikroskopsko (histološko ali citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2020.	38
Table 4a:	Incidence of microscopically (histologically or cytologically) confirmed cancer cases by morphological type, Slovenia 2020.	38
Tabela 4b:	Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2017, Slovenija 2020.	42
Table 4b:	Incidence of malignant neoplasms of lymphoid tissue according to 2017 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2020.	42
Tabela 4c:	Incidenca ne-Hodgkinovih limfomov (NHL) po lokaciji, Slovenija 2020.	43
Table 4c:	Incidence of non-Hodgkin's lymphomas (NHL) by cancer site, Slovenia 2020.	43
Tabela 5:	Incidenca raka po stadiju, Slovenija 2020.	44
Table 5:	Cancer incidence by stage, Slovenia 2020.	44

## Prevalenca 46

Tabela 6:	Prevalenca bolnikov z rakom po spolu, Slovenija, 31. 12. 2020.	46
Table 6:	Prevalence of cancer patients by sex, Slovenia, December 31, 2020.	46

## Umrljivost 47

Tabela 7:	Umrljivost za rakom po starosti in spolu, Slovenija 2020. Vir: Nacionalni inštitut za javno zdravje	47
Table 7:	Cancer mortality by age and by sex, Slovenia 2020. Source: National Institute of Public Health	47

## Preživetje 48

Tabela 8:	Eno- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2016–2020.	48
Table 8:	One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2016–2020 by sex.	48

## Zdravljenje 49

Tabela 9a:	Število in deleži bolnikov (brez primerov, registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2020, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številk v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL).	49
Table 9a:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (in parenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given).	49
Tabela 9b:	Število bolnikov (brez primerov, registriranih samo iz zdravniških poročil o vzroku smrti) v Sloveniji, zbolelih leta 2020, ki so bili v okviru prvega zdravljenja operirani*, po ustanovi posega.	50
Table 9b:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by surgery during their first treatment* by treatment institution.	50
Tabela 9c:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) v Sloveniji, zbolelih leta 2020, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje*, po ustanovi zdravljenja.	51
Table 9c:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by systemic therapy during their first treatment* by treatment institution.	51

<b>Breme najpogostejših rakov</b>	52
Vsi raki / All cancer sites (C00–C96)	52
Prostata / Prostate (C61)	53
Pljuča in sapnik / Lung and trachea (C33, C34)	54
Dojka / Breast (C50)	55
Debelo črevo in danka / Colon and rectum (C18–C20)	56
Koža, razen melanoma / Skin, non-melanoma (C44)	57
Kožni melanom / Malignant melanoma of skin (C43)	58
Glava in vrat / Head and neck (C00–C14, C30–C32)	59
Maternično telo / Corpus uteri (C54)	60
Ne-Hodgkinov limfom / Non-Hodgkin's lymphoma (C82–C85)	61
<b>Pojmovnik</b>	62
<i>Glossary</i>	63

# Uvodnik

Register raka Republike Slovenije je prepoznan kot eden od najstarejših in najkvalitetnejših populacijskih registrov raka v Evropi in svetu. Ustanovljen je bil leta 1950 in vse od začetka deluje na Onkološkem inštitutu Ljubljana. Začetki temeljijo na daljnovidnosti njegove ustanoviteljice in prve vodje, profesorice dr. Božene Ravnihar, ki se je že mnogo let pred tovrstnimi priporočili Svetovne zdravstvene organizacije zavedala, da je uspešnost in učinkovitost prizadevanja služb zdravstvenega varstva in zdravstvene politike za obvladovanje raka mogoče objektivno ovrednotiti le z ustreznimi podatki o bremenu te bolezni in analizami njegovega spreminjanja v času. Leta 2020 smo praznovali 70-letnico neprekinjenega delovanja slovenskega Registra raka. Častljivo obletnico smo zaznamovali tudi s pripravo zgodovinskega pregleda delovanja Registra raka v vseh teh letih. Zainteresiranemu bralcu so zgodovinska dejstva in anekdote prikazani na naši spletni strani ([www.onko-i.si/rrs](http://www.onko-i.si/rrs)) ter v posebej za to priložnost izdani brošuri.

Podatki o novih primerih raka (incidenci), preživetju in prevalenci, ki se zbirajo v Registru raka, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Nacionalni inštitut za javno zdravje, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje Državnega programa obvladovanja raka na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, bolnišnične zmogljivosti). Dragoceni so za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov. Z natančnimi podatki o diagnostiki in zdravljenju, ki jih v Registru raka beležimo v kliničnih registrih, pa lahko poleg zgoraj opisanega spremljamo tudi kakovost obravnave onkoloških bolnikov. Podatki Bolnišničnega registra Onkološkega inštituta Ljubljana, ki že ves čas deluje v sklopu nacionalnega Registra raka ter ga oskrbuje z velikim delom podatkov, pa omogočajo podrobnejši pregled nad bolniki, zdravljenimi na inštitutu.

Redna letna poročila nacionalnega Registra raka so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih. Ker je potreben čas za izdajo letnega poročila nekoliko daljši, v poročilih zadnja leta objavljamo tudi pričakovano incidenco raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2023). Od leta 2010 deluje tudi naš interaktivni spletni portal, ki smo ga po začetnih črkah besed »Slovenija in rak« poimenovali SLORA. Dostopen je na elektronskem naslovu [www.slora.si](http://www.slora.si). Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji ter s hitrim dostopom do tujih baz omogoča primerjavo bremena raka v Sloveniji z drugimi državami v Evropi in po svetu.

Vsem, ki ste kakorkoli prispevali k izdaji tega poročila, tako sodelavcem Registra raka kot tudi vsem zdravnikom in kliničnemu osebju po vsej državi, ki ste nam posredovali poročila o diagnozi in zdravljenju raka, se v imenu uredniškega odbora najlepše zahvaljujem.

prof. dr. Vesna Zadnik, dr. med.  
vodja Registra raka Republike Slovenije

Ljubljana, september 2023

The Slovenian Cancer Registry is recognized as one of the oldest and best-quality population-based cancer registries in Europe and the world. Founded in 1950, it has from the very beginning operated under the auspices of the Institute of Oncology Ljubljana. It was established thanks to the hard work and visionary ideas of its founder and first director, prof dr Božena Ravnihar. Many years before the World Health Organization endorsed such measures, she recognized that the effectiveness and efficiency of the efforts of health services and health policy to manage cancer can be objectively evaluated only with appropriate data on the burden of disease and monitoring of changes over time. In 2020, the Slovenian Cancer Registry celebrated its 70<sup>th</sup> anniversary of continuous operation. To mark this venerable anniversary, we have also prepared a historical overview of the work of the Cancer Registry over all these years. Readers interested in learning more can find historical facts and anecdotes on our website ([www.onko-i.si/eng/crs](http://www.onko-i.si/eng/crs)) and in a brochure published specially for this occasion.

Data on new cancer cases (incidence), survival and prevalence amassed in the Cancer Registry, together with mortality data collected and processed by the National Institute of Public Health, form the basis for assessing cancer burden in the country. The Registry's data are important for planning and evaluation of the National Cancer Control Programme for the primary and secondary prevention of cancer, diagnostics, treatment and rehabilitation, as well as for planning for the facilities and resources needed for cancer management (staff, medical equipment, hospital facilities). They are also extremely useful for Slovenian and international clinical and epidemiological research and for evaluating the effectiveness of screening programmes. In addition, precise data on diagnosis and treatment that the Cancer Registry manages in clinical registries can be used to monitor the quality of treatment received by oncology patients. The Hospital Registry of the Institute of Oncology Ljubljana, which has always been managed as part of the nationwide Cancer Registry and is in large part also supplied with Cancer Registry data, provides a more detailed overview of patients treated at the Institute.

Regular annual reports of the Slovenian Cancer Registry aim to directly inform the professional community and other stakeholders. Given that it takes a fair amount of time to prepare and publish the annual report, the projected cancer incidence for the year when the report is issued (i.e. for 2023 in this report) has in recent years been included in the report. Since 2010, our SLORA interactive web portal – [www.slora.si/en](http://www.slora.si/en) – has also been up and running; its name is based on the initial letters of the words *Slovenija in rak* (Slovenia and cancer). It provides quick and easy access to most cancer data in Slovenia and, with useful links to foreign databases, enables the comparison of cancer burden in Slovenia with other countries in Europe and in the world.

On behalf of the Editorial Board, I would like to sincerely thank everyone who has contributed to the publication of this report, including the staff of the Cancer Registry along with all the physicians and clinical staff across the country who have provided us with reports on cancer diagnosis and treatment.




prof. Vesna Zadnik, MD, PhD  
Director of the Slovenian Cancer Registry

Ljubljana, September 2023



## Viri podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve Registra raka (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92, št. 65/00, št. 47/15 in 31/18). Popolnost zajema podatkov se v Registru raka zagotavlja z vključevanjem različnih virov podatkov, kot je shematsko prikazano na spodnji sliki. Pri povezovanju različnih zbirk se uporablja enoten državni identifikator EMŠO.



Osnovni vir podatkov so slovenski javnozdravstveni zavodi, ki bolezen diagnosticirajo, bolnika zdravijo in spremljajo. Tradicionalno bolnišnice poročajo Registru raka na posebnem formularju Prijavnica rakave bolezni. Na Onkološkem inštitutu Ljubljana (OIL) in deloma na Univerzitetni kliniki Golnik zbirajo podatke za Prijavnico v lastnem bolnišničnem registru ter jih od tam v Register raka posredujejo elektronsko; v preostalih bolnišnicah Prijavnice izpolnjujejo zdravniki, ki bolnika obravnavajo, ali pooblaščen osebje. Skladno s cilji Državnega programa obvladovanja raka 2017–2021 smo v letu 2019 začeli uvajati tako imenovano aktivno registracijo, pri kateri bolnišnice v svojih informacijskih sistemih pripravijo in Registru raka posredujejo seznam bolnikov, ustreznih za registracijo, vse podatke o bolezni in obravnavi za te bolnike pa usposobljeno osebje Registra raka zbira in beleži samo z neposrednim dostopom do elektronske dokumentacije pri izvajalcih. Pasivno poročanje s Prijavnicami tako postopoma ukinjamo. Za zbolele v letu 2020, ki so prikazani v tem poročilu, smo v Registru raka zbrali podatke z aktivno registracijo na Onkološkem inštitutu Ljubljana, Univerzitetnem kliničnem centru Maribor, Pediatrični kliniki ter Kliničnem oddelku za hematologijo Univerzitetnega kliničnega centra Ljubljana.

Dopolnilni vir podatkov Registra raka so podatkovna zbirka o vzrokih smrti, ki jo upravlja Nacionalni inštitut za javno zdravje, ter podatki o diagnosticiranih rakih, ki jih zabeležijo v treh državnih presejalnih programih: ZORA za odkrivanje predrakavih in zgodnjih rakavih sprememb na materničnem vratu, DORA za odkrivanje raka dojk in Svit za odkrivanje predrakavih sprememb in raka na debelem črevesu in danki. Za izračun prevalence in preživetja bolnikov potrebujemo podatek, ki se imenuje vitalno stanje (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo dnevno prek

varnih spletnih povezav iz Centralnega registra prebivalstva (CRP). Podrobne analize prostorske razporeditve raka nam omogočata točno opredeljevanje naslovov bolnikov z rakom in redna povezava z Registrom prostorskih enot (RPE) Geodetske uprave RS (GURS). Pri razporeditvi prebivalcev v geografske enote uporabljamo podatek o stalnem naslovu oseb ob ugotovitvi bolezni, ne pa tudi o začasnem naslovu, kot je upoštevano v pripravi števila prebivalcev po klasični »statistični« definiciji.

Pri izračunavanju in interpretiranju večine kazalnikov bremena raka so poleg podatkov o bolnikih ključni tudi nacionalni podatki o številu prebivalcev in njihovi starostni strukturi. Za Slovenijo sta točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil pripravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja CRP, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 1. julija posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo za leto 2020 so prikazani v tabeli.

Prebivalci Slovenije po starosti in spolu na dan 1. 7. 2020.  
Population of Slovenia by age and sex on July 1<sup>st</sup> 2020.

Starostna skupina Age group	Skupaj All	Moški Males	Ženske Females
0-4	99.951	51.516	48.435
5-9	109.752	56.571	53.181
10-14	106.954	54.984	51.970
15-19	93.674	48.350	45.324
20-24	103.442	55.623	47.819
25-29	113.475	60.739	52.736
30-34	134.316	71.745	62.571
35-39	151.422	80.492	70.930
40-44	160.837	85.373	75.464
45-49	150.023	78.712	71.311
50-54	151.029	77.390	73.639
55-59	150.947	76.018	74.929
60-64	144.449	71.909	72.540
65-69	135.564	66.074	69.490
70-74	101.248	46.901	54.347
75-79	77.562	33.021	44.541
80-84	60.447	23.332	37.115
85+	55.034	15.733	39.301
<b>Skupaj / Total</b>	<b>2.100.126</b>	<b>1.054.483</b>	<b>1.045.643</b>

Vir: Statistični urad RS / Source: Statistical Office of the Republic of Slovenia

## Obdelava podatkov

Podatke, prispele v Register raka, posebej usposobljene medicinske sestre v procesu registracije kodirajo v skladu z mednarodnimi, nacionalnimi in internimi pravili.

### Lokacija tumorja

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), pred tem pa smo uporabljali osmo.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (karcinom in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepitelijske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepitelijske karcinome dojke (šifra D05), od leta 1995 pa intraepitelijske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

## Morfologija tumorja

Pri uvrščanju med maligne bolezni uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo. Od leta 2012 uporabljamo njeno tretjo izdajo z dopolnitvami iz leta 2011, z letom 2020 pa njeno novo različico ICD-O-3.2. Zadnja različica je prinesla posodobitve izrazoslovja, spremembe morfoloških kod in spremembe malignosti tumorjev. Po tej različici so maligni vsi gastrointestinalni stromalni tumorji (GIST) ter skoraj vsi nevroendokrini tumorji in timomi. Pri nevroloških neoplazmah so dodane nove kode. Pomembne spremembe so predvsem pri hematoloških neoplazmah, kjer so nekatere kode za limfome brisane in predstavljene h kodam za levkemije ali obratno. Zadnja različica ne prinaša sprememb v razvrščanju v MKB-10.

Z razvojem molekularne in genske tehnologije je mogoče natančneje opredeliti vrsto celičnih sprememb, ki nastanejo pri neoplazmah krvotvornega in limfatičnega tkiva, in jih zato bolj usmerjeno zdraviti. S tem se večja število različnih vrst bolezni, njihovo razvrščanje pa se vedno bolj izpopolnjuje. Svetovna zdravstvena organizacija je leta 2001 objavila klasifikacijo, ki opredeljuje malignome krvotvornega in limfatičnega tkiva glede na imunofenotip, genske spremembe in klinično sliko. Leta 2017 je bila posodobljena in pri kliničnem delu zamenjuje številne dodatne klasifikacije malignomov krvotvornega in limfatičnega tkiva. Povzema jo tudi Mednarodna klasifikacija bolezni za onkologijo.

## Stadij bolezni

Za prikaz porazdelitve bolezni po stadiju ob diagnozi v letnih poročilih pri solidnih tumorjih uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena (razsejana) bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik predtem ni bil zdravljen. Poenostavljena opredelitev stadijev praviloma sledi klasifikaciji TNM. V omejen stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejen stadij vključeni tudi tumorji T3; pri materničnem vratu, materničnem telesu in sarkomih ter pri jajčniku, jajcevodu in trofoblastnih tumorjih se v omejen stadij uvrščajo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že prisotni v oddaljenih bezgavkah ali organih (M1).

V bazi Registra raka hranimo tudi podatek o stadiju bolezni po klasifikaciji TNM ali drugih klasifikacijah, če je bil tako opredeljen na prijavnici oz. je bilo na njej vsaj dovolj podatkov za njegovo naknadno opredelitev. Dodatno ginekološke tumorje opredeljujemo po klasifikaciji FIGO, pri kožnem melanomu beležimo velikost po Clarku in Breslowu, maligni limfomi pa so opredeljeni po klasifikaciji Ann-Arbor.

## Kakovost podatkov


V Registru raka spremljamo kakovost podatkov z dvema tradicionalnima mednarodno primerljivima posrednima kazalnikoma: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalnikov so prikazane v tabeli.

Incidenca raka glede na način postavitve diagnoze po izbrani primarni lokaciji, Slovenija 2020.  
Cancer incidence according to basis of diagnosis, Slovenia 2020.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri Microscopically confirmed cases		Ugotovljeni z drugimi preiskavami Confirmed by other investigations		Registrirani samo iz zdravniških poročil o vzroku smrti Registered from death certificates only		
			Število Number	%	Število Number	%	Število Number	%	
C00–C96	Vse lokacije All sites	Moški in ženske / Males and females	15096	14223	94,2	839	5,6	34	0,2
		Moški / Males	8062	7582	94,0	466	5,8	14	0,2
		Ženske / Females	7034	6641	94,4	373	5,3	20	0,3
C00–C14	Usta in žrelo / Mouth and pharynx	326	325	99,7	1	0,3	0	0,0	
C15	Požiralnik / Oesophagus	94	91	96,8	3	3,2	0	0,0	
C16	Želodec / Stomach	424	416	98,1	7	1,7	1	0,2	
C18	Debelo črevo / Colon	825	795	96,4	26	3,2	4	0,5	
C19–C20	Rektum in rektosigmoidna zveza / Rectum and rectosigmoid junction	479	464	96,9	14	2,9	1	0,2	
C22	Jetra in intrahepatični vodi / Liver and intrahepatic bile ducts	234	135	57,7	99	42,3	0	0,0	
C23–C24	Žolčnik in žolčevodi / Gallbladder and biliary tract	198	121	61,1	77	38,9	0	0,0	
C25	Trebušna slinavka / Pancreas	420	280	66,7	139	33,1	1	0,2	
C32	Grlo / Larynx	91	90	98,9	1	1,1	0	0,0	
C33–C34	Sapnik, sapnici in pljuča / Trachea, bronchus and lung	1554	1365	87,8	188	12,1	1	0,1	
C43	Maligni melanom kože / Malignant melanoma of skin	639	639	100,0	0	0,0	0	0,0	
C44	Druge maligne neoplazme kože / Skin, excl. melanoma	3010	2998	99,6	10	0,3	2	0,1	
C48–C49	Vezivno in mehko tkivo / Connective and soft tissue	87	84	96,6	3	3,4	0	0,0	
C50	Dojka / Breast	1459	1445	99,0	10	0,7	4	0,3	
C53	Maternični vrat / Cervix uteri	133	131	98,5	2	1,5	0	0,0	
C54	Maternično telo / Corpus uteri	373	370	99,2	3	0,8	0	0,0	
C56	Jajčnik / Ovary	151	139	92,1	12	7,9	0	0,0	
C61	Prostata / Prostate	1460	1407	96,4	45	3,1	8	0,5	
C62	Modo / Testis	112	112	100,0	0	0,0	0	0,0	
C64–C65	Ledvica z ledvičnim mehkom / Kidney with renal pelvis	416	366	88,0	49	11,8	1	0,2	
C67	Sečni mehur / Bladder	387	371	95,9	13	3,4	3	0,8	
C70–C72	Centralni in avtonomni živčni sistem / Central and autonomic nervous system	184	157	85,3	27	14,7	0	0,0	
C73	Ščitnica / Thyroid gland	175	175	100,0	0	0,0	0	0,0	
C81	Hodgkinov limfom / Hodgkin's lymphoma	47	47	100,0	0	0,0	0	0,0	
C82–C85	Ne-Hodgkinovi limfomi / Non-Hodgkin's lymphoma	460	460	100,0	0	0,0	0	0,0	
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	155	155	100,0	0	0,0	0	0,0	
C91–C95	Levkemije / Leukaemias	366	365	99,7	0	0,0	1	0,3	

## Data Sources

Notification of cancer has been compulsory in Slovenia since the foundation of the Slovenian Cancer Registry and is prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92, 65/00, 47/15 and 31/18). Incorporation of data from different sources into the Cancer Registry, as schematically shown in the figure below, ensures data completeness. The unique national identification number (EMŠO) is used to facilitate linkage between different databases.



The main sources of data are Slovenian public healthcare institutions, where diagnostics, treatment and follow-up of patients are carried out. Traditionally, hospitals report cases to the Cancer Registry via the special Cancer Notification Form. At the Institute of Oncology Ljubljana (IOL) and in part also at the University Clinic Golnik, their own hospital registries collect data for the Notification Form and then send it electronically to the Cancer Registry; in other hospitals Notification Forms are filled in by the attending physicians or by the authorized staff. In accordance with the goals of the National Cancer Control Programme 2017–2021, in 2019 we began introducing data collection via so-called active registration, whereby hospital information systems are used to compile and provide the Cancer Registry with a list of patients eligible for registration, whose data on the disease and treatment are then collected and recorded directly from back-office information systems by the trained staff of the Slovenian Cancer Registry. Passive reporting using Notification Forms will gradually be phased out. For patients diagnosed in 2020, whose data are the subject of this report, active registration was employed by the Cancer Registry in collecting the data from the Institute of Oncology Ljubljana and the University Medical Centre Maribor, as well as the Division of Paediatrics and the Department of Haematology at the University Medical Centre Ljubljana.

Complementary sources of information for the Cancer Registry are death certificates that we obtain from the National Institute of Public Health of the Republic of Slovenia and data on diagnosed cancers recorded in three national screening programmes: ZORA for detection of precancerous and early

cancerous cervical lesions, DORA for early detection of breast cancer, and Svit for detection of pre-cancerous lesions and cancer of the colon and rectum. Calculation of cancer prevalence and survival requires information on the patient's vital status (whether the person is alive, dead or lost to follow-up). This data is updated daily through secure electronic linkage with the Central Population Registry (CPR). Detailed analyses of the spatial distribution of cancer are only possible if we have accurately defined addresses of cancer patients, which we obtain through regular linkage to the Register of Spatial Units of the Surveying and Mapping Authority of the Republic of Slovenia (SMARS). When allocating the population to geographical units, we take into account only the permanent residence of persons at the time of diagnosis and not the temporary one, contrary to the standard "statistical" definition of the population used for calculating the number of inhabitants.

In addition to patient data, national population data, especially population size and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration in Slovenia. The census has been performed nearly every 10 years; however, until 1985 no data were available for intermediate years, so for this period it was assumed that the population structure between the two censuses was the same. Since the middle of the eighties, population data are available for any date at the Central Population Registry. In annual reports the population data on 1 July of the relevant year are used, obtained from the SISTAT Database of the Statistical Office of the Republic of Slovenia. In the table on page 9, the population size of Slovenia in 2020 is presented, stratified by age and sex.

## Data Processing

At the Cancer Registry, specially trained nurses code the data retrieved from Cancer Notifications in accordance with international, national and internal guidelines for cancer registration.

### Tumour Location

Since 1997, cancer sites have been coded according to the 10<sup>th</sup> revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10); previously, the 8<sup>th</sup> revision was used (ICD-8).

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Until then, only carcinoma in situ (code 234.0) was registered. Thus, comparisons with data for the period 1961–1992 are not possible. According to ICD-10, all cervical intraepithelial neoplasms (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (code D05) and since 1995, all reported intraepithelial carcinomas of the bladder (code D09.0) and all malignant melanomas of Clark level I (code D03) have been registered as well.

### Tumour Morphology

When classifying tumours as malignant, the behaviour digit of the morphology code of the International Classification of Diseases for Oncology is used. Since 2012, the 3<sup>rd</sup> edition has been in use, including the 2011 updates, and since 2020 its newest revision ICD-O-3.2. The latest revision brought updates in terminology, changes in morphological codes and changes in tumour malignancy. According to this revision, all gastrointestinal stromal tumours (GIST) and nearly all neuroendocrine tumours and thymomas are malignant. New codes have been added in the group of neurological neoplasms. Significant changes have been introduced to haematological neoplasms, where some codes for lymphomas have been deleted and moved to codes for leukaemias or vice versa. The latest revision does not bring any changes in the ICD-10 grouping.

Development of molecular and genetic technologies has enabled more detailed classification of the type of cellular changes found in malignant neoplasms of the lymphoid and haematopoietic tissues. Better and more detailed identification enables targeted treatment. This corresponds to a larger number of disease types with the classification system constantly updating. In 2001, the World Health Organization published a special classification of neoplasms of the lymphoid and haematopoietic tissue based on immunophenotype, genetic changes and clinical picture. The classification was updated in 2017 and it replaced several other classifications of neoplasms of the lymphoid and haematopoietic tissue in clinical use. Furthermore, the International Classification of Diseases for Oncology follows this classification.

## Cancer Staging

For stage description, a simplified definition of stages at diagnosis is used for solid tumours, classifying them into localized, regional and distant stage of disease. The simplified definition is based on all investigation methods, including surgery. If the patient was not treated before death, the autopsy record is considered as well. The simplified stage definition generally follows the TNM classification. Localized stage includes all cancers where the tumour has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer, T3 tumour is also included in the localized stage. In cases of uterine cervix, corpus and sarcomas, ovarian cancer, Fallopian tube and trophoblastic tumours, only T1 tumour is included in the localized stage. In all these cases neither regional lymph node involvement nor distant metastases are found (N0, M0). The regional stage includes tumours classified as T3 and T4 (with aforementioned exceptions) and/or with regional lymph node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). A disease with metastases in distant lymph nodes or organs is classified as a distant stage (M1).

Stage according to TNM or any other appropriate classification, if available, is also stored in the Cancer Registry database. Additionally, FIGO classification is used for gynaecological tumours, Clark's level and Breslow's thickness in skin melanoma, and Ann-Arbor System for lymphomas.

## Data Quality


The quality of information can be directly assessed by the following internationally harmonized standard parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in the table on page 11.

# Rak v Sloveniji

Za dodatne podatke o bremenu raka v Sloveniji in svetu obiščite [www.slora.si](http://www.slora.si).

- Med rojenimi leta 2020 bosta do svojega 75. leta starosti za rakom predvidoma zbolela eden od dveh moških in ena od treh žensk.
- Za rakom zboli letno približno 16.000 Slovencev, več kot 8.000 moških in več kot 7.000 žensk, umre pa jih več kot 6.000, približno 3.500 moških in nekaj manj kot 3.000 žensk; med nami živi že več kot 120.000 ljudi, ki so kadarkoli zboleli zaradi ene od rakavih bolezni (prevalenca).
- Leta 2020, v prvem letu epidemije Covid-19, je bilo diagnosticiranih 11 % manj rakov kot je bilo pričakovano. Največji manko diagnoz je bil pri nemelanomskem kožnem raku, rakah prostate, dojke in pljuč ter pri hematoloških rakah.
- Ogroženost z rakom je največja pri starejših; med vsemi bolniki z rakom, zbolelimi leta 2020, je bilo 65 % starejših od 65 let. Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo.
- Najpogostejši raki pri nas (kože, pljuč, dojke, prostate ter debelega črevesa in danke) so leta 2020 predstavljali 58 % vseh ugotovljenih rakov. Ti raki so povezani z nezdravim življenjskim slogom: kajenjem, čezmernim pitjem alkoholnih pijač, neustrezno prehrano, premalo gibanja in posledično prekomerno težo ter čezmernim sončenjem. Ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive.
- Presejalni programi za rake, ki jih priporoča Svet Evropske unije in smo jih uvedli tudi v Sloveniji, so z zgodnjim odkrivanjem že zmanjšali umrljivost za rakom dojke, debelega črevesa in danke ter rakom materničnega vratu; pri slednjih dveh so zmanjšali tudi incidenco.
- Petletno čisto preživetje odraslih slovenskih bolnikov s katerokoli vrsto raka (brez nemelanomskega kožnega), ki so zboleli v obdobju 2016–2020, je bilo 58 %, bolnic pa 62 %.

Povzetek



Slika 1. Breme raka, Slovenija 2020.  
Figure 1. Cancer burden, Slovenia 2020.




## Osnovni podatki o raku v Sloveniji 2020

- Leta 2020 je v Sloveniji za rakom zbolelo 15.096 ljudi (8.062 moških in 7.034 žensk).
- Starostno standardizirana incidenčna stopnja (evropsko prebivalstvo) je bila 465,5/100.000; 531,9 pri moških in 420,3 pri ženskah. Med rojenimi leta 2020 bosta do svojega 75. leta starosti za rakom predvidoma zbolela eden od dveh moških in ena od treh žensk.
- Leta 2020 je za rakom umrlo 6.423 Slovencev, 3.602 moških in 2.821 žensk. Med nami je živel 124.830 ljudi (57.593 moških in 67.237 žensk), ki so kadarkoli zboleli za eno od rakavih bolezni (prevalenca).
- Med posameznimi slovenskimi regijami ne opažamo bistvenih razlik v bremenu raka.

## Starost bolnikov


- Čeprav se ogroženost z rakom zmeroma večja, je največja v poznejši starosti; med vsemi onkološkimi bolniki je leta 2020 kar 67 % moških in 62 % žensk zbolelo po dopolnjeni starosti 65 let. Polovica odstotka vseh rakavih bolezni je bilo ugotovljenih pri otrocih in mladostnikih (do 20. leta).
- Ker se slovensko prebivalstvo stara, je samo zaradi čedalje večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo. Ocenjujemo, da bomo leta 2023 zabeležili že 17.046 novih bolnikov.



Slika 2. Število novih primerov vseh rakov (desna stran) po starosti ter primerjava s številom prebivalcev (leva stran) v istih starostnih skupinah, Slovenija 2020.  
Figure 2. Number of new cancer cases (right side) by age and comparison with the population numbers (left side) in the same age groups, Slovenia 2020.

## Časovni trend


- V splošnem se groba incidenčna in umrljivostna stopnja raka večata, vendar pa smo v letu 2020, prvem letu epidemije Covid-19, zabeležili 11 % padec v številu novih primerov raka.
- Groba incidenčna stopnja se je v zadnjih 20 letih skoraj podvojila, v zadnjem desetletju se večja za 1,6 % povprečno letno (1,0 % pri moških in 2,4 % pri ženskah). Groba umrljivostna stopnja se je pri moških v zadnjih 10 letih večala povprečno za 0,8 % letno, pri ženskah pa za 1,2 %.
- Več kot polovico tega povečanja lahko pripišemo staranju prebivalstva, saj z daljšo življenjsko dobo lahko tudi več ljudi dočaka to bolezen. Starostno standardizirana kumulativna incidenčna stopnja kaže, da se tveganje raka večja počasneje, pri moških se trend celo obrača navzdol. Spodbudno je tudi, da se umrljivost zaradi raka (če ne upoštevamo staranja prebivalstva) manjša, predvsem od sredine devetdesetih let, kar kaže na večjo uspešnost zdravljenja.



\* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level

Slika 3. Groba letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2020.

Figure 3. Crude annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2020.




\* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level

Slika 4. Kumulativna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo v zadnjih 10 letih, Slovenija 1950–2020.


Figure 4. Cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2020.

## Najpogostejši raki

- Rak ni ena sama bolezen, temveč več sto različnih. Te lahko vzniknejo v vseh tkivih in organih človeškega organizma. Razlikujejo se po pogostosti, zdravljenju in izidu, imajo pa tudi različne bolj ali manj znane nevarnostne dejavnike.
- Pet najpogostejših vrst raka pri nas – kožni (brez melanoma), pljuč, dojke, prostate ter raki debelega črevesa in danke – obsega 58 % vseh novih primerov rakavih bolezni.
- Najpogostejši raki so povezani z nezdravim življenjskim slogom: kajenjem, čezmernim pitjem alkoholnih pijač, neustrezno prehrano, premalo gibanja in posledično prekomerno težo ter čezmernim sončenjem. Ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive.
- Pri moških zavzemata nemelanomski kožni rak in rak prostate vsak približno petino vseh rakov, sledita pljučni rak ter rak debelega črevesa in danke. Pri ženskah je najpogostejši nemelanomski kožni rak, sledi rak dojke, ki predstavlja petino vseh rakov, nato pa še pljučni rak ter rak debelega črevesa in danke.
- Najpogostejši raki se v različnih življenjskih obdobjih pojavljajo različno. Pri otrocih in mladostnikih do 20. leta starosti so najpogostejše levkemije, sledijo jim tumorji centralnega in avtonomnega živčnega sistema in limfomi. Mlajši odrasli (20–49 let) moški zbolevajo največ za rakom mod in kože, pri ženskah v tej starosti pa je na prvem mestu rak dojke.



Slika 5a. Najpogostejše lokacije raka in njihov odstotni delež pri obeh spolih skupaj, Slovenija 2020.  
Figure 5a. The leading cancer sites with percentage distribution for both sexes combined, Slovenia 2020.



\*Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)



Sapnik, sapnici in pljuča / Trachea, bronchus and lung (C33–C34)

Debelo črevo in danka / Colorectum (C18–C20)

Ledvica z ledvičnim mehonom / Kidney with renal pelvis (C64–C65)

Ne-Hodgkinovi limfomi / Non-Hodgkin's lymphoma (C82–C85)

Slika 5b. Najpogostejše lokacije raka in njihov odstotni delež po spolu, Slovenija 2020.  
Figure 5b. The leading cancer sites with percentage distribution by sex, Slovenia 2020.



\*Pojasnilo / Explanation:

Debelo črevo in danka / Colorectum (C18–C20)

Trebušna slinavka / Pancreas (C25)

Pljuča / Lung (C33–C34)

Kosti / Bone (C40–C41)

Koža, melanom / Skin, melanoma (C43)

Koža, razen melanoma / Skin, excl. melanoma (C44)

Veživo in mehko tkivo / Connective and soft tissue (C48–C49)

Glava in vrat / Head and neck (C00–C14, C30–C32)

Dojka / Breast (C50)

Maternični vrat / Cervix uteri (C53)

Maternično telo / Corpus uteri (C54)

Centralni in avtonomi živčni sistem / Central and autonomic nervous system (C70–C72)

Ščitnica / Thyroid gland (C73)

Hodgkinov limfom / Hodgkin's disease (C81)

Levkemije / Leukaemias (C91–C95)

Želodec / Stomach (C16)

Prostata / Prostate (C61)

Modo / Testis (C62)

Ledvica z ledvičnim meh. / Kidney with renal pelvis (C64–C65)


Sečni mehur / Bladder (C67)

Ne-Hodgkinovi limfomi (NHL) / Non-Hodgkin's lymphoma (NHL) (C82–C85)

Slika 6. Odstotni deleži najpogostejših rakov po starostnih skupinah in spolu, Slovenija 2015–2020.  
Figure 6: Percentage distribution of leading cancer sites by age group and sex, Slovenia 2015–2020.


## Trend najpogostejših rakov

- V prvem letu epidemije Covid 2020 je bil največji manko diagnoz pri nemelanomskem kožnem raku, rakah prostate, dojk in pljuč ter pri hematoloških rakah. Nasprotno pa pri rakah debelega črevesa in danke ter pri kožnem melanomu manka ni bilo.
- Med pogostejšimi rakavimi boleznimi pri moških se je incidenčna stopnja pljučnega raka večala vse do začetka novega tisočletja, ko se je ustalila pri vrednosti okoli 90/100.000.
- Pljučnega raka strmo prehitvata rak prostate (sprememba incidenčne stopnje za povprečno -0,6 % na leto) in nemelanomski kožni rak (povečanje za povprečno 4,1 % na leto). Izjemno povečanje incidence raka prostate v zadnjih dveh desetletjih ni posledica kakšnega novega nevarnostnega dejavnika, temveč predvsem vse širše rabe testa za določanje za prostato specifičnega antigena (PSA) pri moških brez zdravstvenih težav in odkrivanja velikega števila primerov, ki bi sicer ostali vse življenje prikriti. Podatki za zadnja leta kažejo, da smo vrh incidence raka prostate že dosegli.
- Tudi časovne spremembe v pojavljanju raka debelega črevesa in danke je treba ocenjevati ob upoštevanju sprememb v diagnostiki – leta 2009 smo namreč v Sloveniji uvedli Državni program presejanja in zgodnjega odkrivanja predrakavih sprememb in raka na debelem črevesu in danki (Svit). Groba incidenčna stopnja raka debelega črevesa in danke pri moških od leta 2011 pada za 2,5 % letno, pred tem pa je v desetletnem obdobju 1999–2008 naraščala vsako leto za 3,6 %. Povprečne letne odstotne spremembe so prikazane ob krivuljah na Sliki 7a.
- Med pogostejšimi rakavimi boleznimi pri ženskah so se večale grobe incidenčne stopnje raka dojk (za 2,6 % povprečno letno), nemelanomskega kožnega raka (povečanje za povprečno 4,5 % letno), pljučnega raka (za 6,3 %) in raka materničnega telesa (za 2,1 %).
- Incidenčna stopnja raka materničnega vratu od uvedbe Državnega programa zgodnjega odkrivanja predrakavih sprememb in raka materničnega vratu (ZORA) pada (za povprečno 1,9 % na leto v zadnjih desetih letih).
- Podobno kot pri moških se tudi pri ženskah zaradi uvedbe presejalnega programa Svit leta 2009 spreminja časovni trend pojavljanja raka debelega črevesa in danke – od leta 2011 groba incidenčna stopnja pada za 1,6 % letno, pred tem pa je med 1999 in 2008 naraščala vsako leto za 3,4 %.



\* Povprečna letna sprememba je statistično značilna pri stopnji tveganja 0,05 / Average annual change is statistically significant at 0.05 significance level


Slika 7a. Groba letna incidenčna stopnja izbranih rakov s povprečno letno spremembo v zadnjih 10 letih pri moških, Slovenija 1950–2020.  
Figure 7a. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years in males, Slovenia 1950–2020.



Slika 7b. Groba letna incidenčna stopnja izbranih rakov s povprečno letno spremembo v zadnjih 10 letih pri ženskah, Slovenija 1950–2020. Figure 7b. Crude annual incidence rates of selected primary cancer sites with average annual change in last 10 years in females, Slovenia 1950–2020.

## Redki raki

- Poseben izziv so redke rakave bolezni (opredeljene kot tiste, ki se jih letno diagnosticira manj kot 6 novih primerov na 100.000 prebivalcev).
- Skupaj so redki raki v Sloveniji predstavljali približno petino vseh novo ugotovljenih primerov raka – letno je za njimi zbolelo približno 3.000 bolnikov.
- Za redke rake je značilno, da se v primerjavi s pogostejšimi večkrat pojavljajo pri otrocih in mladostnikih.
- Kot pri vseh redkih boleznih se tudi pri redkih rakih spopadamo s podobnimi težavami: pozno in težko jih diagnosticiramo, njihov nastanek in možnosti zdravljenja so slabo raziskani ali pa najustreznejše zdravljenje ni široko dostopno. Da bi uspešno obvladovali redke rake, je pomembno, da njihovo breme natančno spremljamo ter da vse države sprejmejo smernice in določijo referenčne centre za diagnostiko in zdravljenje teh bolnikov.



Slika 8: Odstotni delež redkih, pogostih in nerazvrščenih rakov po starostnih skupinah, Slovenija 2004–2013. Figure 8: Percentage distribution of rare, common and unclassified cancers by age group, Slovenia 2004–2013.


## Preživetje

- Petletno čisto preživetje moških bolnikov s katerokoli vrsto raka razen nemelanomskega kožnega, ki so zboleli v obdobju 2016–2020, je bilo že 58,0 %, pri ženskah pa 62,0 %.
- Več kot 80 % je bilo čisto petletno preživetje pri moških z rakom mod, prostate, ščitnice, kožnim melanomom in Hodgkinovim limfomom, pri ženskah pa pri bolnicah z rakom ščitnice, kožnim melanomom, rakom dojk in Hodgkinovim limfomom.
- V letu 2020 je bil narejen pregled preživetij slovenskih onkoloških bolnikov, zbolelih med letoma 1997 in 2016. Rezultati analize so na voljo v publikaciji *Preživetje bolnikov z rakom, zbolelih v letih 1997–2016 v Sloveniji* (Zadnik et al., 2020), ki je v digitalni obliki dostopna na [www.onko-i.si/rrs](http://www.onko-i.si/rrs). Glavni zaključki so:

1. Preživetje slovenskih bolnikov z rakom se s časom povečuje. V zadnjih 20 letih (1997–2001 in 2012–2016) se je petletno čisto preživetje povečalo za 11 odstotnih točk. Občutno večja je rast pri moških, kjer se je petletno čisto preživetje povečalo za 17 odstotnih točk (z 38 % na 55 %). Pri ženskah je petletno čisto preživetje zraslo za 6 odstotnih točk (s 54 % na 60 %).
2. Ključni dejavniki za preživetje bolnikov z rakom so še vedno starost, stadij ob diagnozi in ustrezno zdravljenje. Petletno čisto preživetje je najmanjše pri starejših od 75 let, vendar se je tudi v skupini najstarejših bolnikov v zadnjih 20 letih petletno preživetje izboljšalo za 7 odstotnih točk. Petletno čisto preživetje bolnikov z omejenim stadijem se je v 20 letih povečalo za 10 odstotnih točk; preživetje pri bolnikih z razsejanim stadijem se ne izboljšuje.
3. Pri obeh spolih se je v zadnjih 20 letih značilno povečalo preživetje pri treh pogostih rakah: raku na debelem črevesu in danki (za 14 odstotnih točk z 48 % na 62 %), kožnem melanomu (za 12 odstotnih točk z 79 % na 91 %) ter pri pljučnem raku (za 8 odstotnih točk z 10 % na 18 %). Rezultati kažejo zgodnejšo diagnostiko in napredek pri sistemskem zdravljenju.
4. Občuten je tudi napredek pri obeh najpogostejših rakah, raku dojke pri ženskah in raku prostate pri moških: petletno čisto preživetje bolnic z rakom dojke se je v zadnjih 20 letih povečalo za 10 odstotnih točk, petletno čisto preživetje bolnikov z rakom prostate pa celo za več kot 20 odstotnih točk. Velik napredek pri raku prostate je verjetno samo navidezen, saj smo ravno v obravnavnem obdobju v Sloveniji precej nekritično uporabljali testiranje PSA, s katerim smo odkrivali rake prostate, ki bi po naravnem poteku še dolgo ostali klinično nemi, ter tako z zgodnejšo diagnozo umetno podaljšali preživetje.
5. V skupino rakov, kjer napredka s časom ni opaziti ter pri katerih preživetje še vedno ostaja slabo, pa se uvrščajo rak trebušne slinavke, rak požiralnika, raki jeter, žolčnika in žolčevodov ter možganski tumorji.
6. V raziskavi CONCORD-3 smo primerjali petletna čista preživetja odraslih bolnikov, zbolelimi med letoma 2010 in 2014 v 26 evropskih državah, s 15 različnimi vrstami raka. Preživetje slovenskih bolnikov z rakom je v večini primerov pod evropskim povprečjem, kar nam daje dobro osnovo za nadaljnje izboljšave.
7. Med bolniki z rakom je manj kot 1 % otrok in mladostnikov; zbolevalo predvsem za levkemijami, tumorji osrednjega živčevja in limfomi in imajo boljše petletno preživetje kot odrasli. V zadnjih 20 letih (1997–2001 in 2012–2016) se je petletno preživetje otrok in mladostnikov, zbolelih za rakom, povečalo za 7 odstotnih točk (z 79 % na 86 %).




## Moški Males



Slika 9a. Petletno čisto preživetje (s 95-odstotnim intervalom zaupanja) pri moških, zbolelih za izbranimi raki v letih 2016-2020 in 2011-2015.

Figure 9a. Five-year net survival (with 95% confidence interval) for males diagnosed with selected cancers in periods 2016-2020 and 2011-2015.



Slika 9b. Petletno čisto preživetje (s 95-odstotnim intervalom zaupanja) pri ženskah, zbolelih za izbranimi raki v letih 2016-2020 in 2011-2015.


Figure 9b. Five-year net survival (with 95% confidence interval) for females diagnosed with selected cancers in periods 2016-2020 and 2011-2015.

## Primerjava z Evropo

- Po ocenah Evropskega informacijskega sistema za raka (<https://ecis.jrc.ec.europa.eu/>) je bila Slovenija leta 2022 po incidenčni stopnji (starostno standardizirani na evropsko prebivalstvo) vseh rakov razen kožnega (605/100.000) na osmem mestu med 27 evropskimi državami. Večjo incidence so imele Danska, Irska, Nizozemska, Hrvaška, Madžarska, Belgija in Francija.
- Po umrljivostni stopnji smo na petem mestu, večjo umrljivost so imele Poljska, Madžarska, Hrvaška in Slovaška.

### Ocena incidence po državah Estimated incidence by country


EU-27, vse lokacije brez nemelanomskega kožnega raka, vse starosti, oba spola 2022  
EU-27, all cancer sites excl. non-melanoma skin, all ages, both sexes, 2022



Slika 10a. Ocenjena starostno standardizirana (evropski standard) incidenčna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2022.  
Figure 10a. Estimated age-standardized (European standard) incidence rates of cancer (excluding non-melanoma skin) in Europe, 2022.

## Ocena umrljivosti po državah Estimated mortality by country

EU-27, vse lokacije brez nemelanomskega kožnega raka, vse starosti, oba spola 2022  
EU-27, all cancer sites excl. non-melanoma skin, all ages, both sexes, 2022



Slika 10b. Ocenjena starostno standardizirana (evropski standard) umrljivostna stopnja raka (brez nemelanomskega kožnega) v Evropi, 2022.  
Figure 10b. Estimated age standardized (European standard) mortality rates of cancer (excluding non-melanoma skin) in Europe, 2022.

# Cancer in Slovenia

For additional information on the burden of cancer in Slovenia and in the world, visit: [www.slora.si/en](http://www.slora.si/en). Figures are available on pages 15–27.

## Summary

- Among those born in 2020, one in two men and one in three women are expected to develop cancer by the age of 75.
- Every year around 16,000 Slovenians (more than 8,000 men and more than 7,000 women) are diagnosed with cancer and over 6,000 (about 3,500 men and just under 3,000 women) die of cancer. Currently, there are already over 120,000 people living in Slovenia who have at some point during their lifetime been diagnosed with cancer (prevalence).
- In 2020, the first year of the Covid 19 epidemic, 11% fewer cancers were diagnosed than expected. The greatest shortage of diagnoses occurred in non-melanoma skin cancer, prostate, breast and lung cancers, as well as the hematological cancers.
- The risk of developing cancer increases gradually with age and is highest among the elderly population; of all cancer patients diagnosed in 2020, 65% were over 65 years old. As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of elderly people.
- In 2020, the most frequent cancers in Slovenia (skin, lung, breast, prostate, and colorectal) accounted for 58% of all diagnosed cancers. These cancers are associated with unhealthy lifestyle: smoking, excessive alcohol consumption, unhealthy diet, lack of physical activity and consequential overweight and obesity, and excessive sun exposure – primary prevention measures should be in place with the aim to reduce their burden.
- Cancer screening programmes recommended by the Council of the European Union (EC) that have been introduced in Slovenia have already lowered mortality from breast, colorectal and cervical cancer through early detection; cancer incidence for colorectal and cervical cancers has also been reduced.
- The five-year net survival of adult Slovenian patients with any type of cancer (excluding non-melanoma skin cancer) who were diagnosed in the 2016–2020 period was 58% in men and 62% in women.

## Basic figures on cancer in Slovenia 2020

- In 2020, 15,096 people (8,062 men and 7,034 women) were diagnosed with cancer in Slovenia.
- The age-standardized incidence rate (European standard population) was 465.5/100,000; 531.9 in men and 420.3 in women. Among those born in 2020, one in two men and one in three women are expected to develop cancer by the age of 75.
- In 2020, 6,423 Slovenians died of cancer, 3,602 men and 2,821 women. There were 124,830 people alive in Slovenia (57,593 men and 67,237 women) who had at some point during their lifetime been diagnosed with cancer (prevalence).
- There are no significant differences in the burden of cancer between regions of Slovenia.

## Age of patients

- Although the risk of cancer increases gradually with age, it is by far highest in older age; of all cancer patients in 2020, as many as 67% men and 62% women were diagnosed with cancer after the age of 65. Less than half a percent of all cancers were diagnosed in children and adolescents (up to 20 years of age).

- As the Slovenian population is ageing, the number of new cancer cases is expected to increase simply on account of the growing proportion of elderly people. We estimate that in 2023, there will have been as many as 17,046 newly diagnosed cancer patients.

## Time trends

- In general, the crude incidence and mortality rates of cancer are increasing. However, in 2020, the first year of the Covid 19 epidemic, we recorded an 11% decrease in the number of new cancer cases.
- The crude incidence rate has almost doubled in the last twenty years, increasing by an average of 1.6% per year over the last decade (by 1.0% in men and 2.4% in women). The crude mortality rate has increased on average by 0.8% per year in men over the last 10 years and by 1.2% in women.
- More than half of this increase can be attributed to an ageing population, as longer life expectancy means more people are likely to be diagnosed with cancer. The age-standardized, cumulative incidence rate shows that the risk of cancer adjusted for ageing has been increasing more slowly, with the trend reversed for men. It is also encouraging that cancer mortality (if we adjust for ageing) has been declining, especially since the mid-1990s, pointing to greater successes of cancer treatment.

## Most frequent cancers

- Cancer is not a single disease, but rather several hundred different diseases. These can occur in all tissues and organs of the human body. They vary in frequency, treatment and outcome, and are also associated with different, more or less established risk factors.
- The five most frequent cancers in Slovenia – skin (excluding melanoma), lung, breast, prostate and colorectal – account for 58% of all new cancer cases.
- The most frequent cancers are associated with an unhealthy lifestyle, excessive sun exposure, unhealthy diet, smoking and excessive alcohol consumption. Primary prevention measures should be in place with the aim to reduce their burden.
- In men, prostate cancer and non-melanoma skin cancer account for around one-fifth of all cancers each, followed by lung and colorectal cancer. In women, non-melanoma skin cancer is the most frequent cancer, followed by breast cancer, which accounts for one-fifth of all cancer cases. The next most frequent cancers in women are colorectal and lung cancer.
- The most frequent cancers differ according to age. In children and adolescents aged under 20 years leukaemias are the most frequent, followed by tumours of the central and autonomic nervous system and lymphomas. Young adult men are most often diagnosed with testicular cancer and skin cancer, while in young women breast cancer is ranked first.

## Time trends for most frequent cancers

- In 2020, the first year of the Covid 19 epidemic, the greatest shortage of diagnoses occurred in non-melanoma skin cancer, prostate, breast and lung cancers, as well as the haematological cancers.
- Among the more frequent cancers in men, the incidence rate of lung cancer was increasing until the early 2000s, when it stabilized at around 90/100,000.
- Lung cancer is outranked by the steep rising rates of prostate cancer (crude incidence rate changes at the rate of -0.6% per year on average) and non-melanoma skin cancer (an increase of 4.1% per year on average). The dramatic increase in the incidence of prostate cancer over the

past two decades is not due to any newly identified risk factor, but rather to the increasing use of the prostate-specific antigen (PSA) test in healthy men and therefore detection of a large number of cancers that would have otherwise remained undetected for life. Data for recent years indicate that we have already reached the peak incidence of prostate cancer.

- Time trends in the incidence of colorectal cancer must also be interpreted by taking into account changes in diagnostics – in 2009 Slovenia introduced the national screening and early detection programme for colorectal cancer (Svit). The crude incidence rate of colorectal cancer in men decreased by 2.5% per year from 2011 on, but it was on the rise in 1999–2008 (3.6% on average annually). Average annual percentage changes are shown next to the incidence curves in Figure 7.
- Among the more frequent cancers in women, crude incidence rates have been increasing for breast cancer (by 2.6% on average per year), skin, excluding melanoma (by 4.5% on average per year), lung cancer (by 6.3% on average per year) and corpus uteri cancer (by 2.1% on average per year).
- The incidence rate of cervical cancer has decreased significantly since the introduction of the national cervical cancer screening programme (ZORA) (by an average of 1.9% per year in the last ten years).
- Similar to men, the introduction of the Svit screening programme in 2009 has had an impact on the time trend of colorectal cancer in women – the crude incidence rate of colorectal cancer in women decreased by 1.6% per year from 2011 on, but it was on the rise in the 1999–2008 period (3.4% on average annually).

## Rare cancers

- A particular challenge is posed by rare cancers (defined as those with less than six new cases per 100,000 per year).
- In total, rare cancers in Slovenia accounted for about a fifth of all newly diagnosed cancers – around 3,000 patients were diagnosed with rare cancers every year.
- As opposed to frequent cancers, rare cancers are more likely to occur in children and adolescents.
- Problems with rare cancers are similar to those characteristic of all rare diseases: they are difficult to diagnose and are often detected late, their aetiology and treatment options are poorly researched, or else the most appropriate treatment is hard to access. In order to successfully manage rare cancers, it is important that their burden is closely monitored, and that all countries adopt guidelines as well as establish reference centres for diagnostics and treatment of such patients.

## Survival

- The five-year net survival of male patients with any type of cancer excluding non-melanoma skin cancer diagnosed between 2015 and 2020 was 58.0%, while in women it was 62.0%.
- The five-year net survival was over 80% in men with testicular cancer, prostate cancer, thyroid cancer, skin melanoma and Hodgkin's lymphoma, and in women with thyroid cancer, skin melanoma, breast cancer and Hodgkin's lymphoma.
- In 2020, a survival analysis of Slovenian cancer patients diagnosed between 1997 and 2016 was performed. The results of the analysis are published in the publication *Survival of Cancer Patients, Diagnosed in 1997–2016 in Slovenia* (Zadnik et al., 2021) which is also available in digital format at [www.onko-i.si/eng/crs](http://www.onko-i.si/eng/crs). The main conclusions are on the next page.

1. Survival of Slovenian cancer patients is improving over time. During the 20 years observed (1997–2001 and 2012–2016), five-year net survival increased by 11 percentage points. The increase was significantly higher in men, for whom five-year net survival increased by 17 percentage points (from 38% to 55%). In women, five-year net survival increased by 6 percentage points (from 54% to 60%).
2. Age and stage at diagnosis are still key factors when it comes to survival of cancer patients. Five-year net survival is lowest in those aged 75–94, though even in this age group it has improved by 7 percentage points over the past 20 years. Five-year net survival of patients with localized disease increased by 10 percentage points over the observed 20 years and has reached 85% during the last period; survival of patients with distant disease has not improved.
3. For both sexes combined, survival has improved significantly over the last 20 years for the three most frequent cancers: colorectal cancer (by 14 percentage points, from 48% to 62%), skin melanoma (by 12 percentage points, from 79% to 91%), and lung cancer (by 8 percentage points, from 10% to 18%). This improvement is due to earlier diagnosis and advances in systemic treatment.
4. Progress has also been shown in the two most frequent cancers by sex: breast cancer in women and prostate cancer in men. The five-year net survival of breast cancer patients has increased for 10 percentage points in the last 20 years, while the five-year net survival of prostate cancer patients has increased for over 20 percentage points. The improvement in prostate cancer survival is probably not real, since in the period under review, PSA testing in Slovenia was performed rather uncritically and likely resulted in detection of prostate cancers that would have otherwise remained clinically silent for a long time, thus artificially prolonging survival on account of earlier diagnosis in the natural course of disease.
5. The group of cancers where no progress has been observed over time and where survival still remains low includes pancreatic cancer, oesophageal cancer, liver, gallbladder and bile duct cancers as well as brain tumours.
6. In the CONCORD-3 study, five-year net survival of adult patients with 15 different cancers diagnosed between 2010 and 2014 was compared among 26 European countries. In most cases survival rates of Slovenian cancer patients are below the European average, which highlights the need and serves as an incentive for future improvements.
7. Less than 1% of cancer patients are children and adolescents; they are mainly diagnosed with leukaemias, central nervous system tumours and lymphomas, and have a better five-year survival compared to adults. In the last 20 years (1997–2001 and 2012–2016), the five-year survival of children and adolescents with cancer has increased by 7 percentage points (from 79% to 86%).

## Comparisons with Europe

- In 2022, according to the estimates of the European Cancer Information System (<https://ecis.jrc.ec.europa.eu/>) Slovenia ranked eighth among 27 European countries with respect to the incidence rate (age standardized, European population standard) of all cancers excluding skin cancer (605/100,000). Denmark, Ireland, the Netherlands, Croatia, Hungary, Belgium and France had a higher incidence.
- We are in fifth place in terms of mortality, led by Poland, Hungary, Croatia and Slovakia.



Tabela 1: Opazovana in ocenjena incidenca raka po spolu, Slovenija 2011–2020 in 2023.  
Table 1: Observed and estimated cancer incidence by sex, Slovenia 2011–2020 and 2023.

Šifra MKB	Primarna lokacija	Spol	Povprečne letne opazovane vrednosti 2011–2015		Povprečne letne opazovane vrednosti 2016–2020		Ocena za 2023			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število s 95 % napovednim intervalom		Incidenčna stopnja na 100.000 s 95 % napovednim intervalom	
ICD code	Primary site	Sex	Average annual observed values 2011–2015		Average annual observed values 2016–2020		Estimation for 2023			
			Number	Incidence rate per 100,000	Number	Incidence rate per 100,000	Number with 95% prediction interval		Incidence rate per 100,000 with 95% prediction interval	
C00–C96	Vse lokacije All sites	M+ž M ž	14209 7807 6402	690,2 765,8 616,0	15746 8400 7346	757,8 810,9 705,0	17046 8899 8147	16698–17393 8652–9146 7903–8392	805 837 773	789–822 814–860 750–796
C00–C14	Usta in žrelo Mouth and pharynx	M ž	273 73	26,8 7,0	259 80	25,0 7,7	251 82	210–292 58–107	24 8	20–27 6–10
C15	Požiralnik Oesophagus	M ž	76 16	7,5 1,5	74 19	7,1 1,8	85 22	60–110 11–34	8 2	6–10 1–3
C16	Želodec Stomach	M ž	300 176	29,4 17,0	271 169	26,2 16,2	251 151	210–292 119–182	24 14	20–27 11–17
C18	Debelo črevo Colon	M ž	499 380	48,9 36,6	488 372	47,1 35,7	469 353	429–508 305–402	44 34	40–48 29–38
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M ž	383 215	37,6 20,7	326 189	31,5 18,1	259 159	219–300 124–194	24 15	21–28 12–18
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M ž	154 51	15,1 4,9	174 71	16,8 6,8	200 91	162–239 67–115	19 9	15–22 6–11
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M ž	78 106	7,7 10,2	100 99	9,6 9,5	122 92	91–152 67–117	11 9	9–14 6–11
C25	Trebušna slinavka Pancreas	M ž	193 182	18,9 17,5	218 205	21,1 19,7	248 224	205–290 185–264	23 21	19–27 18–25
C32	Grlo Larynx	M ž	88 12	8,7 1,2	92 13	8,8 1,3	88 12	63–112 3–21	8 1	6–11 0–2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M ž	897 424	88,0 40,8	968 595	93,5 57,1	1039 752	952–1127 683–821	98 71	89–106 65–78
C43	Malignni melanom kože Malignant melanoma of skin	M ž	280 250	27,5 24,1	316 294	30,5 28,3	355 327	304–406 281–373	33 31	29–38 27–35
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M ž	1321 1281	129,6 123,3	1662 1664	160,4 159,7	1998 1957	1879–2116 1824–2090	188 186	177–199 173–198
C48–C49	Veživo in mehko tkivo Connective and soft tissue	M ž	31 43	3,1 4,2	38 41	3,6 4,0	48 39	28–67 23–55	4 4	3–6 2–5
C50	Dojka Breast	M ž	13 1292	1,3 124,4	12 1481	1,2 142,2	12 1649	3–21 1543–1754	1 156	0–2 146–166
C53	Maternični vrat Cervix uteri	M ž	– 124	– 11,9	– 111	– 10,6	– 99	– 74–123	– 9	– 7–12
C54	Maternično telo Corpus uteri	M ž	– 333	– 32,0	– 367	– 35,2	– 403	– 351–456	– 38	– 33–43
C56	Jajčnik Ovary	M ž	– 161	– 15,5	– 151	– 14,5	– 150	– 118–181	– 14	– 11–17
C61	Prostata Prostate	M ž	1620 –	158,9 –	1648 –	159,2 –	1578 –	1475–1682 –	148 –	139–158 –
C62	Modo Testis	M ž	113 –	11,1 –	109 –	10,6 –	117 –	87–147 –	11 –	8–14 –
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M ž	251 134	24,6 12,9	284 138	27,5 13,2	310 140	263–357 108–172	29 13	25–34 10–16
C67	Sečni mehur Bladder	M ž	250 86	24,5 8,3	259 103	25,0 9,9	266 115	221–311 86–143	25 11	21–29 8–14
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	M ž	87 69	8,6 6,6	103 73	10,0 7,0	122 84	91–152 60–107	11 8	9–14 6–10
C73	Ščitnica Thyroid gland	M ž	46 126	4,5 12,1	49 150	4,8 14,4	57 175	37–76 141–209	5 17	4–7 13–20
C81	Hodgkinov limfom Hodgkin's lymphoma	M ž	21 24	2,1 2,3	28 28	2,7 2,6	37 30	20–54 16–45	3 3	2–5 2–4
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M ž	201 200	19,8 19,2	231 223	22,3 21,4	266 253	219–313 212–295	25 24	21–29 20–28
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M ž	69 71	6,7 6,8	86 70	8,3 6,7	93 76	67–119 53–98	9 7	6–11 5–9
C91–C95	Levkemije Leukaemias	M ž	190 139	18,7 13,3	211 163	20,3 15,7	234 186	201–266 149–224	22 18	19–25 14–21

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka po spolu, Slovenija 2020.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates by sex, Slovenia 2020.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR* – World standard	SSS* – evropski standard ASR* – European standard	SSS* – slovenski standard ASR* – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	15096	718,8	327,0	465,5	554,0
		M	8062	764,5	363,5	531,9	646,4
		Ž	7034	672,7	302,6	420,3	490,1
C00–C14	Usta in žrelo Mouth and pharynx	M	252	23,9	12,8	17,9	20,0
		Ž	74	7,1	3,5	4,9	5,4
C15	Požiralnik Oesophagus	M	81	7,7	3,7	5,3	6,4
		Ž	13	1,2	0,4	0,7	0,8
C16	Želodec Stomach	M	279	26,5	11,3	17,5	21,9
		Ž	145	13,9	5,1	7,5	9,2
C18	Debelo črevo Colon	M	482	45,7	20,9	31,3	38,1
		Ž	343	32,8	13,2	18,8	22,3
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	300	28,4	13,8	20,1	23,8
		Ž	179	17,1	7,0	10,1	11,8
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	169	16,0	7,3	10,9	13,4
		Ž	65	6,2	2,0	3,0	3,9
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	108	10,2	4,5	6,8	8,6
		Ž	90	8,6	2,5	4,0	5,1
C25	Trebušna slinavka Pancreas	M	210	19,9	8,9	13,5	16,7
		Ž	210	20,1	6,7	10,3	12,7
C32	Grlo Larynx	M	81	7,7	3,9	5,5	6,4
		Ž	10	1,0	0,5	0,7	0,7
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	935	88,7	41,0	60,4	73,7
		Ž	619	59,2	24,7	35,5	42,3
C43	Malignni melanom kože Malignant melanoma of skin	M	330	31,3	16,7	23,4	27,4
		Ž	309	29,6	16,0	21,2	24,3
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M	1571	149,0	64,4	99,6	125,2
		Ž	1439	137,6	52,9	77,4	93,4
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	44	4,2	2,4	3,1	3,6
		Ž	43	4,1	2,4	3,0	3,3
C50	Dojka Breast	M	11	1,0	0,4	0,7	1,0
		Ž	1448	138,5	72,8	98,3	111,1
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	133	12,7	8,2	10,4	11,5
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	373	35,7	16,7	23,5	26,6
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	151	14,4	7,5	9,9	11,3
C61	Prostata Prostate	M	1460	138,5	62,2	93,4	116,0
		Ž	–	–	–	–	–
C62	Modo Testis	M	112	10,6	9,7	10,6	11,4
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	279	26,5	13,2	18,8	22,1
		Ž	137	13,1	5,0	7,4	8,9
C67	Sečni mehur Bladder	M	271	25,7	10,9	16,9	21,4
		Ž	116	11,1	3,2	5,1	6,5
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	M	105	10,0	6,6	8,1	9,0
		Ž	79	7,6	5,2	5,7	5,9
C73	Ščitnica Thyroid gland	M	52	4,9	3,3	4,1	4,6
		Ž	123	11,8	7,9	9,6	10,7
C81	Hodgkinov limfom Hodgkin's lymphoma	M	21	2,0	1,9	2,0	2,2
		Ž	26	2,5	2,6	2,6	2,8
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	234	22,2	11,6	16,2	19,4
		Ž	226	21,6	9,7	13,4	15,7
C90	Difuzni plazmocitomi in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	77	7,3	3,4	5,1	6,0
		Ž	78	7,5	2,9	4,3	5,2
C91–C95	Levkemije Leukaemias	M	219	20,8	12,0	15,5	17,9
		Ž	147	14,1	7,2	9,1	10,4

\* SSS – starostno standardizirana incidenčna stopnja na 100.000  
ASR – age standardized incidence rate per 100,000

Tabela 3: Incidenca raka po starosti in spolu ter groba stopnja (GS) na 100.000 prebivalcev in kumulativna stopnja (KS), Slovenija 2020.  
Table 3: Cancer incidence by age and by sex with crude rate (GS) per 100,000 population and cumulative rate (KS), Slovenia 2020.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost / Age																	GS	KS 0-74		
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-			85+	
C00 - C96	Vse lokacije All sites	M+Ž	15096	24	18	14	25	34	67	131	248	394	564	884	1247	1686	2357	2216	2061	1683	1443	718,8	37,8	
		M	8062	14	8	6	12	20	30	61	89	144	224	401	645	976	1417	1348	1199	913	555	764,5	42,8	
		Ž	7034	10	10	8	13	14	37	70	159	250	340	483	602	710	940	868	862	770	888	672,7	33,6	
C00	Ustnica Lip	M	16	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2	3	4	2	1,5	0,1
		Ž	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	2	3	2	1,1	0,0
C01	Baza jezika Base of tongue	M	21	0	0	0	0	0	0	0	0	0	1	1	2	4	4	5	1	2	0	1	2,0	0,1
		Ž	4	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1	1	0	0	0	0,4	0,0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	27	0	0	0	0	0	1	0	0	0	2	7	5	4	1	4	1	1	1	1	2,6	0,2
		Ž	7	0	0	0	0	0	0	0	0	0	0	1	2	0	1	1	1	0	1	0	0,7	0,0
C03	Dleseni Gum	M	7	0	0	0	0	0	0	0	0	0	1	1	0	0	2	0	1	2	0	0,7	0,0	
		Ž	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0,3	0,0	
C04	Ustno dno Floor of mouth	M	18	0	0	0	0	0	0	0	0	1	1	2	3	4	1	2	2	1	1	1,7	0,1	
		Ž	6	0	0	0	0	0	0	0	0	0	1	2	0	2	0	1	0	0	0	0,6	0,0	
C05	Nebo Palate	M	9	0	0	0	0	0	0	0	0	1	0	1	3	2	1	1	0	0	0	0,9	0,1	
		Ž	7	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1	1	1	1	1	0,7	0,0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	7	0	0	0	0	0	0	0	0	0	0	1	2	1	0	1	1	0	1	0,7	0,0	
		Ž	6	0	0	0	0	0	0	0	0	1	0	0	3	0	0	0	0	2	0	0,6	0,0	
C07	Parotidna žleza Parotid gland	M	8	0	0	0	0	0	0	0	0	0	1	1	1	2	1	1	1	0	0	0,8	0,1	
		Ž	6	0	0	0	0	0	0	0	0	0	1	1	1	1	1	0	0	0	0	0,6	0,0	
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0,1	0,0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0,1	0,0	
C09	Tonzila Tonsil	M	33	0	0	0	0	0	0	0	0	1	4	5	5	6	8	0	2	2	0	3,1	0,2	
		Ž	14	0	0	0	0	0	0	0	0	1	0	2	3	2	2	2	1	0	1	1,3	0,1	
C10	Orofarinks Oropharynx	M	31	0	0	0	0	0	0	0	0	0	0	7	5	7	6	4	1	1	0	2,9	0,2	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0,1	0,0	
C11	Nazofarinks Nasopharynx	M	5	0	0	0	0	0	0	0	0	0	1	0	3	1	0	0	0	0	0	0,5	0,0	
		Ž	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0,1	0,0	
C12	Piriformni sinus Pyriform sinus	M	39	0	0	0	0	0	0	0	1	1	0	4	9	10	8	4	2	0	0	3,7	0,3	
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	0	0	0	0,3	0,0	
C13	Hipofarinks Hypopharynx	M	28	0	0	0	0	0	0	0	0	0	0	1	4	6	10	5	1	1	0	2,7	0,2	
		Ž	4	0	0	0	0	0	0	0	0	0	0	1	2	1	0	0	0	0	0	0,4	0,0	
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0,2	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0	
C15	Požiralnik Oesophagus	M	81	0	0	0	0	0	0	0	0	1	3	5	6	18	13	10	12	6	7	7,7	0,4	
		Ž	13	0	0	0	0	0	0	0	0	0	0	1	2	0	2	2	1	3	2	1,2	0,1	
C16	Želodec Stomach	M	279	0	0	0	0	0	0	0	4	1	7	10	17	33	41	39	49	53	25	26,5	1,2	
		Ž	145	0	0	0	0	0	1	0	2	2	6	6	7	13	18	20	23	19	28	13,9	0,6	
C17	Tanko črevo Small intestine	M	28	0	0	0	0	0	0	0	0	0	2	0	3	2	9	4	2	3	3	2,7	0,2	
		Ž	22	0	0	0	0	0	0	0	1	1	0	1	7	1	2	2	3	2	2	2,1	0,1	
C18	Debelo črevo Colon	M	482	0	0	1	1	0	2	2	3	7	16	28	40	48	74	78	60	78	44	45,7	2,4	
		Ž	343	0	2	1	0	1	2	2	4	5	13	23	22	26	39	53	40	55	55	32,8	1,5	
C19	Rektosigmoidna zveza Rectosigmoid junction	M	64	0	0	0	0	0	0	1	2	3	1	4	4	11	11	4	7	11	5	6,1	0,3	
		Ž	35	0	0	0	0	0	0	0	2	1	1	3	1	2	8	4	3	5	5	3,3	0,2	
C20	Rektum Rectum	M	236	0	0	0	0	0	0	0	1	10	8	25	18	35	39	30	29	28	13	22,4	1,3	
		Ž	144	0	0	0	0	0	0	0	4	4	4	13	12	13	23	15	14	18	24	13,8	0,6	
C21	Anus in analni kanal Anus and anal canal	M	10	0	0	0	0	0	0	0	0	1	0	0	0	2	2	3	1	1	0	0,9	0,1	
		Ž	14	0	0	0	0	0	0	0	0	0	1	0	6	1	1	1	1	0	3	1,3	0,1	
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	169	0	0	0	0	0	0	0	0	1	2	1	18	23	44	38	27	12	3	16,0	1,0	
		Ž	65	0	0	0	0	0	0	0	0	0	1	2	3	3	9	13	10	18	6	6,2	0,2	
C23	Žolčnik Gallbladder	M	24	0	0	0	0	0	0	0	0	1	1	1	2	0	4	2	4	5	4	2,3	0,1	
		Ž	33	0	0	0	0	0	0	0	0	0	0	0	1	2	4	6	7	6	7	3,2	0,1	
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspec- ified parts	M	84	0	0	0	0	0	0	0	0	0	5	2	3	12	14	16	14	7	11	8,0	0,4	
		Ž	57	0	0	0	0	0	0	0	0	0	0	1	1	3	12	10	6	10	14	5,5	0,2	
C25	Trebušna slinavka Pancreas	M	210	0	0	0	0	0	0	1	0	4	5	10	18	24	31	38	33	24	22	19,9	1,1	
		Ž	210	0	0	0	0	0	0	0	2	2	2	8	13	16	26	30	38	36	37	20,1	0,8	

Nadaljevanje →  
Continued →

Tabela 3: Nadaljevanje.  
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages		Starost / Age																	GS	KS 0-74	
			0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+				
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0,1	0,0
		Ž	5	0	0	0	0	0	1	0	0	0	0	0	0	0	1	2	0	0	0	1	0,5	0,0
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	8	0	0	0	0	0	0	0	0	0	1	1	1	1	2	0	2	0	0	0	0,8	0,0
		Ž	6	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0	0	2	0,6	0,0
C31	Obnosni sinusi Accessory sinuses	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0,1	0,0
		Ž	2	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0,2	0,0
C32	Grlo Larynx	M	81	0	0	0	0	0	0	0	0	1	3	7	9	15	23	12	5	5	1	7,7	0,5	
		Ž	10	0	0	0	0	0	0	0	0	0	0	0	5	1	4	0	0	0	0	1,0	0,1	
C33	Sapnik Trachea	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0,1	0,0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0,1	0,0
C34	Sapnica in pljuča Bronchus and lung	M	934	0	0	0	0	0	0	0	6	14	31	83	145	230	179	130	75	41	88,6	5,5		
		Ž	618	1	0	0	0	0	1	1	8	9	22	57	95	132	116	84	53	39	59,1	3,3		
C37	Timus Thymus	M	9	0	0	0	0	0	0	1	0	0	0	2	1	1	2	0	1	0	0,9	0,1		
		Ž	6	0	0	0	0	0	0	0	0	0	0	1	0	1	4	0	0	0	0,6	0,1		
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	4	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0,4	0,0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0,1	0,0	
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0	
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	3	0	0	1	1	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0,3	0,0	
		Ž	6	0	0	1	0	2	0	0	0	0	0	0	0	0	0	1	1	1	0	0,6	0,0	
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	3	0	0	1	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0,3	0,0	
		Ž	2	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0,2	0,0	
C43	Malignni melanom kože Malignant melanoma of skin	M	330	0	0	0	2	1	3	7	7	16	20	31	39	32	35	52	39	30	16	31,3	1,9	
		Ž	309	0	0	0	2	2	4	10	14	21	28	34	25	15	32	27	40	24	31	29,6	1,6	
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M	1571	0	0	0	1	2	3	6	16	29	48	54	95	136	213	251	297	253	167	149,0	6,9	
		Ž	1439	0	0	0	1	1	4	8	27	31	49	78	92	133	152	205	218	185	255	137,6	5,9	
C45	Mezoteliom Mesothelioma	M	25	0	0	0	0	0	0	0	0	0	1	7	3	3	6	3	0	2	2,4	0,2		
		Ž	8	0	0	0	0	0	0	0	0	0	1	1	1	0	0	2	1	2	0,8	0,0		
C46	Kaposijev sarkom Kaposi's sarcoma	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0,1	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0	
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	2	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0,2	0,0	
		Ž	2	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0,2	0,0	
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	12	1	1	0	0	0	0	0	0	0	0	2	3	1	3	0	1	0	1,1	0,1		
		Ž	15	0	1	0	0	0	0	0	0	1	0	3	1	4	2	0	1	2	1,4	0,1		
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	32	0	0	0	0	0	0	2	4	0	4	1	2	3	3	6	3	4	3,0	0,1		
		Ž	28	0	0	0	1	1	1	1	0	1	1	4	2	2	2	7	1	2	2,7	0,1		
C50	Dojka Breast	M	11	0	0	0	0	0	0	0	0	1	0	0	1	3	5	0	1	1,0	0,0			
		Ž	1448	0	0	0	0	5	20	58	89	127	152	154	170	220	128	116	96	113	138,5	8,1		
C51	Žensko zunanje spolovilo Vulva	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	54	0	0	0	0	0	0	0	0	0	1	3	5	8	6	9	12	10	5,2	0,2		
C52	Nožnica Vagina	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	8	0	0	0	0	0	0	0	0	1	0	1	1	2	0	1	2	0	0,8	0,0		
C53	Maternični vrat Cervix uteri	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	133	0	0	0	0	5	10	12	15	8	13	14	13	8	13	11	6	5	12,7	0,8		
C54	Maternično telo Corpus uteri	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	373	0	0	0	0	0	1	4	11	13	36	56	56	59	47	32	31	27	35,7	2,1		
C55	Maternica, neopredeljeno Uterus, unspecified	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	15	0	0	0	0	0	0	0	0	1	2	1	3	2	3	1	1	1,4	0,1			
C56	Jajčnik Ovary	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	151	0	1	1	1	0	2	7	8	14	11	14	14	17	17	13	15	16	14,4	0,8		
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
		Ž	38	0	0	0	0	0	0	0	0	2	3	1	3	5	10	3	5	4	2	3,6	0,2	

Nadaljevanje →  
Continued →

Tabela 3: Nadaljevanje.  
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost / Age																	GS	KS 0-74	
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-			85+
C58	Posteljica Placenta	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis Penis	M	16	0	0	0	0	0	0	0	0	2	0	0	2	1	1	2	5	2	1	1,5	0,1
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C61	Prostata Prostate	M	1460	0	0	0	0	0	0	0	0	2	10	44	115	213	318	331	233	122	72	138,5	8,5
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C62	Modo Testis	M	112	0	0	1	0	10	10	27	25	16	12	5	3	0	1	0	2	0	0	10,6	0,8
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	4	0	0	0	0	0	0	0	0	0	0	2	1	1	0	0	0	0	0	0,4	0,0
		Ž	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
C64	Ledvica razen meha Kidney, excl. renal pelvis	M	254	2	0	0	0	0	1	1	4	5	9	20	29	33	52	33	25	26	14	24,1	1,4
		Ž	122	0	0	0	0	0	0	0	1	3	4	5	10	11	18	13	20	22	15	11,7	0,5
C65	Ledvični meh Renal pelvis	M	25	0	0	0	0	0	0	0	0	1	1	0	0	3	4	5	3	7	1	2,4	0,1
		Ž	15	0	0	0	0	0	0	1	0	1	1	1	1	1	2	2	4	0	1	1,4	0,1
C66	Sečevod Ureter	M	14	0	0	0	0	0	0	0	0	0	0	4	1	3	0	2	3	1	0	1,3	0,1
		Ž	7	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	2	0	2	0,7	0,0
C67	Sečni mehur Bladder	M	271	0	0	0	0	0	0	0	1	2	3	13	7	32	46	49	49	46	23	25,7	1,3
		Ž	116	0	0	0	0	0	0	0	0	2	1	0	3	6	19	16	18	13	38	11,1	0,4
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0
C69	Oko in očesni adneksi Eye and adnexa	M	15	1	0	0	0	0	0	0	1	1	1	2	1	1	3	1	1	1	1	1,4	0,1
		Ž	17	1	0	0	0	0	0	0	0	0	0	2	1	0	4	2	3	1	3	1,6	0,1
C70	Meninge Meninges	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0,2	0,0
		Ž	2	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0,2	0,0
C71	Možgani Brain	M	102	2	1	1	0	2	4	2	5	4	8	8	10	14	16	11	8	3	3	9,7	0,7
		Ž	73	5	3	1	1	0	0	0	2	1	3	3	8	5	6	8	11	12	4	7,0	0,4
C72	Hrbtini mozeg, možganski živci in drugi deli CŽS Spinal cord, cranial nerves and other parts of CNS	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0,1	0,0
		Ž	4	0	0	0	0	0	0	1	0	1	1	0	0	1	0	0	0	0	0	0,4	0,0
C73	Ščitnica Thyroid gland	M	52	0	0	0	2	1	1	1	2	2	7	7	7	2	10	7	1	2	0	4,9	0,4
		Ž	123	0	0	0	3	1	7	5	7	12	11	12	12	5	17	9	9	10	3	11,8	0,8
C74	Nadledvična žleza Adrenal gland	M	4	0	0	0	0	0	0	0	1	0	1	0	2	0	0	0	0	0	0	0,4	0,0
		Ž	8	1	0	0	0	0	0	0	0	2	0	0	1	0	2	1	1	0	0	0,8	0,1
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0,1	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0,1	0,0
		Ž	12	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	2	1	6	1,1	0,0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	24	0	0	0	0	0	0	1	0	0	2	2	1	2	4	2	2	6	2	2,3	0,1
		Ž	14	0	0	0	0	0	0	0	0	0	0	1	0	3	1	2	2	0	5	1,3	0,1
C78	Metastaze dihal in prebavi Metastases of respiratory and digestive organs	M	22	0	0	0	0	0	0	0	0	0	0	0	1	2	2	3	2	3	9	2,1	0,1
		Ž	37	0	0	0	0	0	0	0	0	2	0	1	3	2	1	4	1	8	15	3,5	0,1
C79	Metastaze, drugje Metastases of other sites	M	13	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	5	1	2	1,2	0,0
		Ž	10	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	3	5	1,0	0,0
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	59	0	0	0	0	0	0	0	0	0	1	3	2	7	14	9	7	8	8	5,6	0,3
		Ž	56	0	0	0	0	0	0	0	0	3	2	0	2	9	6	8	3	7	16	5,4	0,2
C81	Hodgkinov limfom Hodgkin's lymphoma	M	21	0	0	0	1	2	3	3	2	1	3	2	2	0	0	1	1	0	0	2,0	0,1
		Ž	26	0	0	0	3	2	5	3	1	3	0	1	1	1	1	2	1	0	2	2,5	0,2
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	58	0	1	1	0	0	1	0	1	0	0	9	7	5	10	11	7	3	2	5,5	0,4
		Ž	77	0	0	0	0	0	0	1	2	1	6	9	10	14	8	8	8	5	5	7,4	0,4
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	142	0	0	0	3	1	0	1	4	1	6	8	11	17	22	24	26	11	7	13,5	0,8
		Ž	126	0	0	1	1	1	1	3	2	3	5	4	5	16	9	15	19	21	20	12,1	0,5

Nadaljevanje —>  
Continued —>

Tabela 3: Nadaljevanje.  
Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost / Age																	GS	KS 0-74	
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-			85+
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	22	0	0	0	0	0	0	1	0	2	1	1	1	2	7	5	2	0	0	2,1	0,2
		Ž	13	0	0	0	0	0	0	1	0	1	0	1	0	0	2	1	7	0	0	1,2	0,0
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	12	0	0	0	0	0	0	0	0	1	0	1	0	1	2	1	3	2	1	1,1	0,0
		Ž	10	0	0	0	0	0	0	0	0	0	0	0	1	2	0	2	1	0	4	1,0	0,0
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0,4	0,0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0,2	0,0
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	77	0	0	0	0	0	0	0	0	1	2	5	12	10	15	7	11	9	5	7,3	0,4
		Ž	78	0	0	0	0	0	0	0	0	1	1	3	7	4	10	10	7	15	8	12	7,5
C91.0	Limfoblastna levkemija Lymphoblastic leukaemia, acute	M	18	6	5	0	0	0	0	2	3	1	0	0	0	1	0	0	0	0	0	1,7	0,1
		Ž	17	2	3	2	0	0	1	0	1	1	2	0	1	1	1	2	0	0	0	1,6	0,1
C91.1- C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	99	0	0	0	0	0	0	2	1	1	4	7	8	8	16	12	14	17	9	9,4	0,5
		Ž	61	0	0	0	0	0	0	0	1	1	7	4	3	4	2	10	10	12	7	5,8	0,2
C92	Mieločna levkemija Myeloid leukaemia	M	67	1	0	0	1	1	0	1	3	4	3	2	3	7	6	11	8	9	7	6,4	0,3
		Ž	47	0	0	1	0	0	0	1	1	1	1	4	3	4	5	4	7	9	7	4,5	0,2
C93	Monocitna levkemija Monocytic leukaemia	M	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	0	0,4	0,0
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	0	0,4	0,0
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	27	0	0	0	0	0	0	1	0	2	1	1	0	3	5	6	7	1	0	2,6	0,2
		Ž	18	0	0	0	0	0	0	0	0	2	2	1	2	2	4	0	2	2	1	1,7	0,1
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	2	0,4	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	0,0
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	107	0	0	0	0	0	0	0	2	1	4	4	9	18	13	28	18	10	10,1	0,4	
		Ž	106	0	0	0	0	2	0	0	1	1	1	2	7	8	11	10	19	24	20	10,1	0,3

Zgoraj ne vključeni:  
Not included above:

D03	Melanom, in situ Melanoma, in situ	M	182	0	0	0	0	1	2	5	7	6	6	18	11	14	27	32	31	10	12	17,3	1,0
		Ž	153	0	0	0	2	4	2	5	11	11	15	15	16	13	12	13	19	9	6	14,6	0,9
D05	Dojka, in situ Breast, in situ	M	3	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	0	0	0	0,3	0,0
		Ž	189	0	0	0	0	0	0	0	1	9	20	52	21	38	37	4	6	1	0	18,1	1,3
D06	Maternični vrat, in situ (CIN III) Cervix uteri, in situ	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	977	0	0	0	0	81	188	159	155	132	94	54	48	32	14	12	5	2	1	93,4	7,6
D09.0	Sečni mehur, in situ Bladder, in situ	M	196	0	0	0	0	0	0	1	1	3	4	8	13	24	48	41	23	15	15	18,6	1,2
		Ž	74	0	0	0	0	0	0	0	1	1	1	6	5	13	9	14	13	7	4	7,1	0,4
D32.0, D42.0	Meninge, benigna neoplazma negotovega značaja Benign neoplasm and neoplasm of uncertain behaviour of meninges	M	55	0	0	1	0	0	0	0	2	0	3	2	6	6	13	7	6	4	5	5,2	0,3
		Ž	111	0	0	0	0	0	1	1	3	6	7	9	8	21	10	17	8	17	3	10,6	0,6
D33.0- D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	8	2	2	1	1	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0,8	0,1
		Ž	3	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	1	0	0	0,3	0,0
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		Ž	63	0	0	0	1	2	6	7	4	2	6	6	7	12	4	3	3	0	0	6,0	0,5
D43.0- D43.2	Možgani, neopredeljeno Central nervous system (CNS), uncertain or unknown	M	8	0	0	1	1	0	0	0	1	0	1	2	1	0	0	0	1	0	0	0,8	0,1
		Ž	4	0	0	0	0	0	0	1	0	2	0	1	0	0	0	0	0	0	0	0,4	0,0

Tabela 4a: Incidenca mikroskopsko (histološko ali citološko) potrjenih primerov raka po morfološki vrsti, Slovenija 2020.  
 Table 4a: Incidence of microscopically (histologically or cytologically) confirmed cancer cases by morphological type, Slovenia 2020.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																			
		Primary site (ICD code)																			
		C00-C80	C00	C01	C02	C03	C04	C05	C06	C07	C08	C09	C10	C11	C12	C13	C14	C15	C16	C17	C18
Vse vrste / All types	12977	27	24	34	10	24	16	13	14	2	47	32	6	42	32	2	91	416	47	795	
Small cell carcinoma	215	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	
Non-small cell carcinoma	66	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Squamous cell carcinoma	1567	27	24	34	10	24	12	6	1	0	47	32	5	41	30	2	62	2	0	1	
Basal cell carcinoma	2380	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Transitional cell carcinoma	425	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Adenocarcinoma	6792	0	0	0	0	0	2	6	6	1	0	0	1	0	0	0	26	371	28	789	
Other specified carcinomas	153	0	0	0	0	0	2	0	6	0	0	0	0	1	1	0	1	2	1	1	
Carcinoma, unspecified	121	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4	2	3	
Malignant thymoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant paraganglioma/pheochromocytoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant melanoma	690	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0	
Fibrosarcoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Fibrohistiocytic sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Liposarcoma	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Leiomyosarcoma	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Rhabdomyosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Angiosarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Chondrosarcoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Ewing sarcoma/PNET	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified sarcomas	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Sarcoma, unspecified	29	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	
Malignant complex mixed and stromal tumors	95	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	1	36	15	1	
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant mesothelioma	33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant gonadal stromal tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dysgerminoma and seminoma	81	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other malignant germ cell tumors	36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant trophoblastic tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant gliomas	154	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant neuroepithelial tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant nerve sheath tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant tumor, unspecified	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Nadaljevanje —>  
 Continued —>

Tabela 4a: Nadaljevanje.  
Table 4a: Continued.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																		
		Primary site (ICD code)																		
		C00-C80	C19	C20	C21	C22	C23	C24	C25	C26	C30	C31	C32	C33	C34	C37	C38	C39	C40	C41
Vse vrste / All types	12977	93	371	23	135	37	84	280	4	13	3	90	2	1363	15	2	0	9	5	639
Small cell carcinoma	215	0	1	0	0	0	0	0	0	1	0	0	0	198	0	0	0	0	0	0
Non-small cell carcinoma	66	0	0	0	0	0	0	0	0	0	0	0	0	66	0	0	0	0	0	0
Squamous cell carcinoma	1567	0	3	13	0	1	0	0	0	5	1	90	1	310	2	0	0	0	0	0
Basal cell carcinoma	2380	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	425	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Adenocarcinoma	6792	93	362	8	130	33	77	256	3	5	1	0	1	728	0	0	0	0	0	0
Other specified carcinomas	153	0	1	1	0	2	2	4	0	1	1	0	0	43	0	0	0	0	0	0
Carcinoma, unspecified	121	0	0	0	1	1	5	20	1	0	0	0	0	14	0	0	0	0	0	0
Malignant thymoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	13	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant melanoma	690	0	1	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	639
Fibrosarcoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	24	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	5	0	0	0	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	0
Chondrosarcoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Ewing sarcoma/PNET	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Other specified sarcomas	3	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	29	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
Malignant complex mixed and stromal tumors	95	0	3	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	81	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other malignant germ cell tumors	36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	154	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
Malignant tumor, unspecified	7	0	0	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0

Nadaljevanje —>  
Continued —>



Tabela 4a: Nadaljevanje.  
Table 4a: Continued.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																		
		Primary site (ICD code)																		
		C00-C80	C44	C45	C46	C47	C48	C49	C50	C51	C52	C53	C54	C55	C56	C57	C58	C60	C61	C62
Vse vrste / All types	12977	2998	33	1	4	25	59	1445	53	8	131	370	12	139	37	0	16	1407	112	
Small cell carcinoma	215	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	
Non-small cell carcinoma	66	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Squamous cell carcinoma	1567	585	0	0	0	0	0	0	44	6	105	0	0	0	0	0	16	0	0	
Basal cell carcinoma	2380	2375	0	0	0	0	0	0	3	0	1	0	0	0	0	0	0	0	0	
Transitional cell carcinoma	425	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7	0	
Adenocarcinoma	6792	21	0	0	0	6	0	1391	4	0	19	301	0	114	34	0	0	1396	0	
Other specified carcinomas	153	1	0	0	0	0	0	21	0	0	5	48	0	1	0	0	0	1	0	
Carcinoma, unspecified	121	6	0	0	0	0	0	28	0	0	0	1	0	7	1	0	0	0	0	
Malignant thymoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant paraganglioma/pheochromocytoma	8	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant melanoma	690	0	0	0	0	0	0	0	2	2	0	0	0	0	0	0	0	0	0	
Fibrosarcoma	13	1	0	0	0	1	10	0	0	0	0	0	0	0	0	0	0	0	0	
Fibrohistiocytic sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Liposarcoma	24	0	0	0	0	10	11	0	0	0	0	0	0	0	0	0	0	0	0	
Leiomyosarcoma	22	4	0	0	0	3	6	0	0	0	0	0	9	0	0	0	0	0	0	
Rhabdomyosarcoma	2	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	
Synovial sarcoma	5	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	0	0	0	
Angiosarcoma	5	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
Kaposi sarcoma	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Chondrosarcoma	3	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	
Ewing sarcoma/PNET	3	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified sarcomas	3	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	
Sarcoma, unspecified	29	4	0	0	0	1	19	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant complex mixed and stromal tumors	95	0	0	0	0	1	0	0	0	0	1	20	3	7	2	0	0	0	0	
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	5	0	0	0	0	0	0	0	0	0	0	0	
Malignant mesothelioma	33	0	33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant gonadal stromal tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	
Dysgerminoma and seminoma	81	0	0	0	0	1	0	0	0	0	0	0	0	3	0	0	0	0	76	
Other malignant germ cell tumors	36	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	35	
Malignant trophoblastic tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
Malignant gliomas	154	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant neuroepithelial tumors	6	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant meningioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant nerve sheath tumors	2	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Malignant tumor, unspecified	7	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Nadaljevanje —>  
Continued —>

Tabela 4a: Nadaljevanje.  
Table 4a: Continued.

Histološka vrsta Histologic type	Skupaj All Sites	Primarna lokacija (šifra MKB) Primary site (ICD code)																	
		Primary site (ICD code)																	
		C00–C80	C63	C64	C65	C66	C67	C68	C69	C70	C71	C72	C73	C74	C75	C76	C77	C78	C79
Vse vrste / All types	12977	4	326	40	19	371	0	23	4	149	4	175	12	1	8	36	32	9	72
Small cell carcinoma	215	0	0	0	0	4	0	0	0	0	0	0	0	0	0	3	0	0	3
Non-small cell carcinoma	66	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Squamous cell carcinoma	1567	0	0	1	0	1	0	1	0	0	0	0	0	0	0	17	0	1	4
Basal cell carcinoma	2380	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Transitional cell carcinoma	425	0	0	39	19	359	0	0	0	0	0	0	0	0	0	0	1	0	0
Adenocarcinoma	6792	0	320	0	0	3	0	0	0	0	0	171	5	0	5	8	21	1	45
Other specified carcinomas	153	0	0	0	0	1	0	0	0	0	0	2	0	0	0	3	0	0	0
Carcinoma, unspecified	121	0	4	0	0	3	0	0	0	0	0	1	0	0	1	2	7	1	8
Malignant thymoma	13	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant paraganglioma/pheochromocytoma	8	0	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0	0	0
Malignant melanoma	690	0	0	0	0	0	0	20	1	0	0	0	0	0	0	2	2	6	11
Fibrosarcoma	13	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
Fibrohistiocytic sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Liposarcoma	24	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Leiomyosarcoma	22	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Rhabdomyosarcoma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Synovial sarcoma	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Angiosarcoma	5	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
Kaposi sarcoma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Osteosarcoma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chondrosarcoma	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ewing sarcoma/PNET	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified sarcomas	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sarcoma, unspecified	29	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Malignant complex mixed and stromal tumors	95	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant fibroepithelial tumors	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant mesothelioma	33	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gonadal stromal tumors	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dysgerminoma and seminoma	81	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
Other malignant germ cell tumors	36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant trophoblastic tumors	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant gliomas	154	0	0	0	0	0	0	0	0	149	4	0	0	1	0	0	0	0	0
Malignant neuroepithelial tumors	6	0	0	0	0	0	0	2	0	0	0	0	1	0	0	0	0	0	0
Malignant meningioma	2	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
Malignant nerve sheath tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other specified malignant tumors	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Malignant tumor, unspecified	7	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1

Tabela 4b:

Incidenca malignih neoplazem limfatičnega tkiva v skladu s klasifikacijo Svetovne zdravstvene organizacije iz leta 2017, Slovenija 2020.

Table 4b:

Incidence of malignant neoplasms of lymphoid tissue according to 2017 version of Classification of Tumours of Haematopoietic and Lymphoid Tissues (published by World Health Organization), Slovenia 2020.

Šifra ICD-0-3 ICD-0-3 code	Histološka vrsta Histology type	Število Number
Vse vrste All types	Moški in ženske / Males and females Moški / Males Ženske / Females	864 454 410
9727, 9835, 9811-9819	Neoplazme nezrelih celic B Precursor lymphoid neoplasms B	27
9835, 9811	Limfoblastna levkemija B / limfom B, BDO B lymphoblastic leukaemia / lymphoma, NOS	18
9812, 9814, 9815, 9816	Limfoblastna levkemija B / limfom B z rekurentnimi citogenetskimi anomalijami B lymphoblastic leukaemia / lymphoma with recurrent genetic abnormalities	9
9837	Neoplazme nezrelih celic T Precursor lymphoid neoplasms T	8
9837	Limfoblastna levkemija T / limfom T T Lymphoblastic leukaemia / lymphoma	8
9591-9597, 9671-9699, 9712, 9731-9738, 9760-9764, 9823, 9833, 9940, 9766	Periferni B-celični limfom / neoplazme zrelih celic B Mature B-cell neoplasms	737
9823	Kronična limfatična levkemija B / drobnocelični limfocitni limfom Chronic lymphocytic leukaemia / small lymphocytic lymphoma	147
9689	Splenični limfom robne cone Splenic marginal zone lymphoma	22
9591	Ne-Hodgkinovi limfomi, BDO; primarni vranični limfom / levkemija, nerazvrščeni; difuzni drobnocelični limfom B rdeče pulpe; posebna oblika dlakastocelične levkemije Non-Hodgkin lymphoma, NOS; splenic B-cell lymphoma / leukaemia, unclassifiable; splenic diffuse red pulp small B-cell lymphoma; hairy cell leukaemia-variant	16
9940	Dlakastocelična levkemija Hairy cell leukaemia	8
9671	Limfoplazmatični limfom Lymphoplasmacytic lymphoma	7
9761	Waldenströmova makroglobulinemija Waldenström macroglobulinemia	6
9732	Multipli mielom Plasma cell myeloma	147
9731, 9734	Solitarni kostni in zunajkostni plazmatom Solitary plasmacytoma of bone and extrasosseous	8
9699, nodalni	B-celični limfom robne cone, nodalni Marginal zone B-cell lymphoma, nodal	45
9699, ekstranodalni	B-celični limfom robne cone, ekstranodalni Marginal zone B-cell lymphoma, extranodal	26
9690	Folikularni limfom, BDO Follicular lymphoma, NOS	8
9691, 9695	Folikularni limfom, gradus 1 in 2 Follicular lymphoma, grade 1 and 2	37
9698	Folikularni limfom, gradus 3 Follicular lymphoma, grade 3	18
9597	Primarni kožni limfom folikularnih centrov Primary cutaneous follicle centre lymphoma	1
9673	Limfom plaščnih celic Mantle cell lymphoma	29
9735	Plazmablastni limfom Plasmablastic lymphoma	2
9680	Difuzni velikocelični limfom B (DLBCL), BDO; primarni DLBCL ČŽS; primarni kožni DLBCL, nožni tip; EBV-pozitivni DLBCL starejših; DLBCL povezan s kroničnim vnetjem; nerazvrščeni B-celični limfom, mejni pri mer med difuznim velikoceličnim limfomom B in Burkittovim limfomom Malignant lymphoma, large B-cell, diffuse (DLBCL), NOS; primary DLBCL of the CNS; primary cutaneous DLBCL, leg type; EBV positive DLBCL of the elderly; DLBCL associated with chronic inflammation; B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma	192

Šifra ICD-0-3 ICD-0-3 code	Histološka vrsta Histology type	Število Number
9687	Burkittov limfom / levkemija Burkitt lymphoma / leukaemia	7
9679	Primarni mediastinalni (timični) velikocelični limfom B Primary mediastinal (thymic) large B-cell lymphoma	8
9596	Sestavljeni (kompozitni) Hodgkinov in non-Hodgkinov limfom Composite Hodgkin and non-Hodgkin lymphoma	2
9688	Velikocelični B-celični limfom bogat z limfociti T in histiociti T-cell/histiocyte rich large B-cell lymphoma	1
	Neoplazme zrelih celic T/NK Mature T- and NK-cell neoplasms	39
9827, 9831, 9834, 9948	Levkemične neoplazme zrelih celic T/NK Leukaemic mature T- and NK-cell neoplasms	4
9831	Levkemija velikih granuliranih limfocitov T T-cell large granular lymphocytic leukemia	3
9834	Prolimfocitna levkemija T T-cell prolymphocytic leukaemia	1
9700, 9701, 9708, 9709, 9716-9719	Neoplazme zrelih (ekstranodalnih) celic T/NK Mature (extranodal) T- and NK-cell neoplasms	13
9719	Ekstranodalni limfom NK/T, nazalni Extranodal NK/T-cell lymphoma, nasal type	1
9708	Podkožni panikulitisu podoben limfom T Subcutaneous panniculitis-like T-cell lymphoma	1
9700	Fungoidna mikoza Mycosis fungoides	7
9701	Sézaryjev sindrom Sézary syndrome	2
9718	Primarne kožne CD30+ T-celične limfoproliferativne bolezni Primary cutaneous CD30+ T-cell lymphoproliferative disorder	2
9702, 9705, 9714, 9715	Zrele (nodalne) neoplazme celic T/NK Mature (nodal) T- and NK-cell neoplasms	22
9702	Periferni limfom T, BDO Peripheral T-cell lymphoma, NOS	10
9705	Angioimunoblastni limfom T Angioimmunoblastic T-cell lymphoma	9
9714	Anaplastični velikocelični limfom, ALK-pozitivni Anaplastic large cell lymphoma, ALK positive	1
9715	Anaplastični velikocelični limfom, ALK-negativni Anaplastic large cell lymphoma, ALK negative	2
9650-9667	Hodgkinov limfom (HL) Hodgkin lymphoma (HL)	47
9659	HL z nodularno limfocitno prevladanco Nodular lymphocyte predominant HL	5
9650	Klasični HL Classical HL	3
9663	Klasični HL, tip nodularne skleroze Nodular sclerosis classical HL	24
9651	Z limfociti bogat klasični HL Lymphocyte-rich classical HL	3
9652	Mešanocelični tip klasičnega HL Mixed cellularity classical HL	12
9590, 9832	Neopredeljeni limfomi / levkemije Unspecified lymphoma / leukemia	4
9590	Maligni limfom, BDO Malignant lymphoma, NOS	4
9750-9759	Neoplazme histiocitov in dendritičnih celic Histiocytic and dendritic cell neoplasms	2
9755	Histiocitni sarkom Histiocytic sarcoma	2

BDO - brez drugih oznak / NOS - not otherwise specified, EBV - Epstein-Barr virus, ČŽS - centralni živčni sistem / CNS - central nervous system, NK - natural killer cells, ALCL - anaplastični velikocelični limfom / anaplastic large cell lymphoma

Tabela 4c: Incidenca ne-Hodgkinovih limfomov (NHL) po lokaciji, Slovenija 2020.  
 Table 4c: Incidence of non-Hodgkin's lymphomas (NHL) by cancer site, Slovenia 2020.

Šifra MKB-8 ICD-8 code	Primarna lokacija Primary site	Vse starosti All ages
	<b>Vsi NHL</b> All NHL	460
141	<b>Jezik</b> Tongue	1
142	<b>Slinavke</b> Salivary glands	2
143	<b>Dlesni</b> Gum	1
145	<b>Usta, drugo</b> Mouth, other parts	2
146	<b>Orofarinks</b> Oropharynx	8
151	<b>Želodec</b> Stomach	18
152	<b>Tanko črevo</b> Small intestine	3
153	<b>Debelo črevo</b> Colon	2
160	<b>Nos, obnosne votline, drugo</b> Nos, obnosne votline, drugo	4
162	<b>Sapnik, sapnica, pljuča</b> Trachea, bronchus, lung	5
163	<b>Plevra, mediastinum, drugo</b> Pleura, mediastinum, etc.	1
170	<b>Kosti</b> Bone	3
171	<b>Mehka tkiva</b> Soft tissues	1
173	<b>Koža, drugi malignomi</b> Skin, other malignancies	22
174	<b>Dojka</b> Breast	3
186	<b>Modo</b> Testis	3
190	<b>Okó</b> Eye	7
191	<b>Možgani</b> Brain	10
192	<b>Živčevje, drugo</b> Nervous system, other	1
193	<b>Ščitnica</b> Thyroid	4
194	<b>Endokrine žleze, druge</b> Endocrine glands, other	3
202	<b>Bezgavke</b> Lymph nodes	356

Tabela 5: Incidenca raka po stadiju, Slovenija 2020.  
Table 5: Cancer incidence by stage, Slovenia 2020.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Stadij / Stage							
			Omejen Localized		Razširjen Regional		Razsejan Distant		Neznano Unknown **	
			Število Number	%*	Število Number	%*	Število Number	%*	Število Number	%*
C00-C80	Moški in ženske / Males and females	13849	7539	54,6	3466	25,1	2705	19,6	139	0,8
	Vse lokacije / All sites	7400	3889	52,7	1955	26,5	1475	20,0	81	0,9
	Moški / Males	6449	3650	56,8	1511	23,5	1230	19,1	58	0,6
	Ženske / Females									
C00	Ustnica / Lip	27	24	88,9	3	11,1	0	0,0	0	0,0
C01	Baza jezika / Base of tongue	25	3	12,0	21	84,0	1	4,0	0	0,0
C02	Jezik, drugi deli / Tongue, other & unspecified parts	34	11	32,4	23	67,6	0	0,0	0	0,0
C03	Dlesen / Gum	10	1	-	9	-	0	-	0	-
C04	Ustno dno / Floor of mouth	24	7	29,2	16	66,7	1	4,2	0	0,0
C05	Nebo / Palate	16	8	50,0	6	37,5	2	12,5	0	0,0
C06	Usta, drugi deli / Mouth, other & unspecified parts	13	5	-	8	-	0	-	0	-
C07	Parotidna žleza / Parotid gland	14	9	-	5	-	0	-	0	-
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	2	1	-	0	-	1	-	0	-
C09	Tonzila / Tonsil	47	6	12,8	39	83,0	2	4,3	0	0,0
C10	Orofaring / Oropharynx	32	4	12,5	26	81,3	2	6,3	0	0,0
C11	Nazofaring / Nasopharynx	6	1	-	5	-	0	-	0	-
C12	Piriformni sinus / Piriform sinus	42	2	4,8	35	83,3	5	11,9	0	0,0
C13	Hipofaring / Hypopharynx	32	0	0,0	28	87,5	4	12,5	0	0,0
C14	Druge in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	2	0	-	2	-	0	-	0	-
C15	Požiralnik / Oesophagus	94	8	8,5	49	52,1	34	36,2	3	3,2
C16	Želodec / Stomach	424	77	18,2	163	38,4	174	41,0	10	2,4
C17	Tanko črevo / Small intestine	50	9	18,0	15	30,0	25	50,0	1	2,0
C18	Debelo črevo / Colon	825	162	19,6	467	56,6	189	22,9	7	0,8
C19	Rektosigmoidna zveza / Rectosigmoid junction	99	10	10,1	54	54,5	34	34,3	1	1,0
C20	Rektum / Rectum	380	96	25,3	191	50,3	86	22,6	7	1,8
C21	Anus in analni kanal / Anus and anal canal	24	9	37,5	13	54,2	2	8,3	0	0,0
C22	Jetra in intrahepatični vodi / Liver and intrahepatic bile ducts	234	75	32,1	65	27,8	93	39,7	1	0,4
C23	Žolčnik / Gallbladder	57	11	19,3	16	28,1	28	49,1	2	3,5
C24	Druge in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	141	29	20,6	57	40,4	54	38,3	1	0,7
C25	Trebušna slinavka / Pancreas	420	70	16,7	129	30,7	217	51,7	4	1,0
C26	Druge in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	6	0	-	1	-	3	-	2	-
C30	Nosna votlina in srednje uho / Nasal cavity and middle ear	14	3	-	11	-	0	-	0	-
C31	Obnosni sinusi / Accessory sinuses	3	1	-	1	-	0	-	1	-
C32	Grla / Larynx	91	42	46,2	44	48,4	5	5,5	0	0,0
C33	Sapnik / Trachea	2	1	-	1	-	0	-	0	-
C34	Sapnica in pljuča / Bronchus and lung	1552	355	22,9	375	24,2	820	52,8	2	0,1
C37	Timus / Thymus	15	12	80,0	0	0,0	3	20,0	0	0,0
C38	Srce, mediastinum, plevra / Heart, mediastinum, pleura	5	0	-	2	-	2	-	1	-
C39	Druge in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	0	0	-	0	-	0	-	0	-
C40	Kosti, sklepni hrustanec udov / Bone and articular cartilage of limbs	9	3	-	4	-	2	-	0	-
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	5	2	-	2	-	1	-	0	-
C43	Maligni melanom kože / Malignant melanoma of skin	639	487	76,2	138	21,6	12	1,9	2	0,3
C44	Druge maligne neoplazme kože / Skin, excl. melanoma	3010	2889	96,0	116	3,9	2	0,1	3	0,1
C45	Mezoteliom / Mesothelioma	33	8	24,2	18	54,5	7	21,2	0	0,0
C46	Kaposijev sarkom / Kaposi's sarcoma	1	1	-	0	-	0	-	0	-
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	4	2	-	1	-	1	-	0	-
C48	Peritonej in retroperitonej / Retroperitoneum and peritoneum	27	1	3,7	15	55,6	11	40,7	0	0,0
C49	Drugo vezivno in mehko tkivo / Other connective and soft tissue	60	18	30,0	31	51,7	11	18,3	0	0,0
C50	Dojka / Breast	1459	882	60,5	457	31,3	115	7,9	5	0,3

Nadaljevanje —>  
Continued —>

Tabela 5: Nadaljevanje.  
Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Stadij / Stage							
			Omejen Localized		Razširjen Regional		Razsejan Distant		Neznan Unknown**	
			Število Number	%*	Število Number	%*	Število Number	%*	Število Number	%*
C51	Žensko zunanje spolovilo / Vulva	54	27	50,0	22	40,7	3	5,6	2	3,7
C52	Nožnica / Vagina	8	4	-	4	-	0	-	0	-
C53	Maternični vrat / Cervix uteri	133	61	45,9	49	36,8	23	17,3	0	0,0
C54	Maternično telo / Corpus uteri	373	254	68,1	75	20,1	36	9,7	8	2,1
C55	Maternica, neopredeljeno / Uterus, unspecified	15	8	53,3	2	13,3	3	20,0	2	13,3
C56	Jajčnik / Ovary	151	25	16,6	19	12,6	107	70,9	0	0,0
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	38	2	5,3	3	7,9	33	86,8	0	0,0
C58	Posteljica / Placenta	0	0	-	0	-	0	-	0	-
C60	Penis / Penis	16	11	68,8	4	25,0	1	6,3	0	0,0
C61	Prostata / Prostate	1460	864	59,2	395	27,1	171	11,7	30	2,1
C62	Modo / Testis	112	89	79,5	12	10,7	10	8,9	1	0,9
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	4	3	-	1	-	0	-	0	-
C64	Ledvica razen meha / Kidney, excl. renal pelvis	376	223	59,3	64	17,0	87	23,1	2	0,5
C65	Ledvični meh / Renal pelvis	40	9	22,5	19	47,5	12	30,0	0	0,0
C66	Sečevod / Ureter	21	8	38,1	9	42,9	4	19,0	0	0,0
C67	Sečni mehur / Bladder	387	258	66,7	76	19,6	48	12,4	5	1,3
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	0	0	-	0	-	0	-	0	-
C69	Oko in očesni adneksi / Eye and adnexa	32	29	90,6	2	6,3	1	3,1	0	0,0
C70	Meninge / Meninges	4	4	-	0	-	0	-	0	-
C71	Možgani / Brain	175	173	98,9	1	0,6	1	0,6	0	0,0
C72	Hrbtni mozeg, možganski živci in drugi deli centralnega živčnega sistema (ČZS) Spinal cord, cranial nerves and other parts of central nervous system (CNS)	5	5	-	0	-	0	-	0	-
C73	Ščitnica / Thyroid gland	175	128	73,1	41	23,4	6	3,4	0	0,0
C74	Nadledvična žleza / Adrenal gland	12	8	-	1	-	3	-	0	-
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	1	1	-	0	-	0	-	0	-
C76	Druga in slabo opredeljena mesta / Other and ill-defined sites	13	0	-	5	-	7	-	1	-
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	38	0	0,0	0	0,0	3	7,9	35	92,1
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	59	0	0,0	0	0,0	59	100,0	0	0,0
C79	Metastaze, drugje / Metastases of other sites	23	0	0,0	0	0,0	23	100,0	0	0,0
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	115	0	0,0	0	0,0	115	100,0	0	0,0

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Stadij / Stage						Neznan / Unknown	
			I		II		III + IV		Število Number	%*
			Število Number	%*	Število Number	%*	Število Number	%*		
C81	Hodgkinov limfom / Hodgkin's lymphoma	47	1	2,1	18	38,3	27	57,4	1	2,1
C82	Folikularni ne-Hodgkinov limfom / Follicular non-Hodgkin's lymphoma	135	37	27,4	14	10,4	79	58,5	5	3,7
C83	Difuzni ne-Hodgkinov limfom / Diffuse non-Hodgkin's lymphoma	268	52	19,4	32	11,9	167	62,3	17	6,3
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	35	9	25,7	3	8,6	21	60,0	2	5,7
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	22	2	9,1	2	9,1	16	72,7	2	9,1

\* Odstotki niso računani, če je število novih primerov manjše od 15  
Percentages are not calculated when number of new cases is less than 15

\*\* Vključeni tudi primeri, ki so registrirani samo iz zdravniških poročil o vzroku smrti, razen pri C78-C80, kjer so prišteti k razsejanemu stadiju  
Cases registered from death certificates only are included, except for C78-C80, where they are added to the distant stage

Tabela 6: Prevalenca bolnikov z rakom po spolu, Slovenija, 31. 12. 2020.  
Table 6: Prevalence of cancer patients by sex, Slovenia, December 31, 2020.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence
			<1	1-4	5-9	10+	Vsi / All
C00-C96	Vse lokacije All sites	M+Ž	12223	39787	33100	49222	124830
		M	6386	20078	16780	19521	57593
		Ž	5837	19709	16320	29701	67237
C00-C14	Usta in žrelo Mouth and pharynx	M	204	540	434	556	1734
		Ž	68	209	174	302	753
C15	Požiralnik Oesophagus	M	39	53	29	22	143
		Ž	10	12	7	14	43
C16	Želodec Stomach	M	179	346	291	415	1231
		Ž	94	229	190	383	896
C18	Debelo črevo Colon	M	394	1158	1064	1314	3930
		Ž	283	936	854	1316	3389
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	250	842	836	1103	3031
		Ž	148	459	465	913	1985
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	83	125	40	26	274
		Ž	28	48	12	14	102
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	54	68	38	42	202
		Ž	40	60	43	47	190
C25	Trebušna slinavka Pancreas	M	117	120	35	30	302
		Ž	94	102	41	40	277
C32	Grlo Larynx	M	71	255	198	356	880
		Ž	10	42	26	58	136
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	572	1008	433	428	2441
		Ž	423	819	313	250	1805
C43	Malignni melanom kože Malignant melanoma of skin	M	318	1024	972	1220	3534
		Ž	299	1029	958	1944	4230
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M	1521	5806	4522	5008	16857
		Ž	1401	6141	4651	6193	18386
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	M	39	86	69	214	408
		Ž	37	92	87	220	436
C50	Dojka Breast	M	11	40	38	36	125
		Ž	1384	5157	4577	8715	19833
C53	Maternični vrat Cervix uteri	M	-	-	-	-	-
		Ž	120	303	381	2631	3435
C54	Maternično telo Corpus uteri	M	-	-	-	-	-
		Ž	346	1142	1129	2432	5049
C56	Jajčnik Ovary	M	-	-	-	-	-
		Ž	122	343	259	934	1658
C61	Prostata Prostate	M	1358	5692	5374	4183	16607
		Ž	-	-	-	-	-
C62	Modo Testis	M	112	419	529	1709	2769
		Ž	-	-	-	-	-
C64-C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	233	745	582	827	2387
		Ž	107	340	329	547	1323
C67	Sečni mehur Bladder	M	227	554	438	471	1690
		Ž	86	193	132	171	582
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	69	110	66	195	440
		Ž	48	62	45	159	314
C73	Ščitnica Thyroid gland	M	51	168	174	304	697
		Ž	118	589	560	1306	2573
C81	Hodgkinov limfom Hodgkin's lymphoma	M	19	98	79	390	586
		Ž	24	96	98	369	587
C82-C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	186	581	473	648	1888
		Ž	184	598	498	667	1947
C90	Difuzni plazmocitomi in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	71	201	92	72	436
		Ž	63	153	90	78	384
C91-C95	Levkemije Leukaemias	M	189	480	379	556	1604
		Ž	111	392	291	472	1266

\* Pri posameznih lokacijah je pri prikazu prevalence oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat  
Person diagnosed with more than one cancer is included as a prevalent case in each cancer site, but for all sites together (C00-C96) each person is counted once only

Tabela 7: Umrljivost za rakom po starosti in spolu, Slovenija 2020. Vir: Nacionalni inštitut za javno zdravje  
 Table 7: Cancer mortality by age and by sex, Slovenia 2020. Source: National Institute of Public Health

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost / Age			
				0-19	20-49	50-74	75+
C00-C97	Vse lokacije All sites	M+Ž	6423	8	200	2834	3381
		M	3602	5	83	1794	1720
		Ž	2821	3	117	1040	1661
C00-C14	Usta in žrelo Mouth and pharynx	M	139	0	7	111	21
		Ž	20	0	1	8	11
C15	Požiralnik Oesophagus	M	97	0	5	65	27
		Ž	19	0	0	6	13
C16	Želodec Stomach	M	194	0	6	80	108
		Ž	119	0	5	39	75
C18	Debelo črevo Colon	M	234	0	6	89	139
		Ž	179	0	11	50	118
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	170	0	2	92	76
		Ž	98	0	6	27	65
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	212	0	1	142	69
		Ž	90	0	3	32	55
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	54	0	0	29	25
		Ž	59	0	0	19	40
C25	Trebušna slinavka Pancreas	M	209	0	7	108	94
		Ž	209	0	9	80	120
C32	Grlo Larynx	M	49	0	1	29	19
		Ž	4	0	0	2	2
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	742	0	15	488	239
		Ž	451	0	9	251	191
C43	Maligni melanom kože Malignant melanoma of skin	M	74	0	3	36	35
		Ž	67	0	9	26	32
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M	26	0	1	6	19
		Ž	34	0	0	3	31
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	M	15	0	2	7	6
		Ž	19	0	2	4	13
C50	Dojka Breast	M	3	0	0	1	2
		Ž	472	0	33	175	264
C53	Maternični vrat Cervix uteri	M	-	-	-	-	-
		Ž	38	0	4	16	18
C54	Maternično telo Corpus uteri	M	-	-	-	-	-
		Ž	77	0	0	31	46
C56	Jajčnik Ovary	M	-	-	-	-	-
		Ž	107	0	4	55	48
C61	Prostata Prostate	M	460	0	1	128	331
		Ž	-	-	-	-	-
C62	Modo Testis	M	5	0	3	1	1
		Ž	-	-	-	-	-
C64-C65	Ledvica z ledvičnim mehom Kidney with renal pelvis	M	101	0	2	40	59
		Ž	71	0	2	22	47
C67	Sečni mehur Bladder	M	179	0	0	69	110
		Ž	63	0	1	7	55
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	83	2	11	48	22
		Ž	80	2	5	37	36
C73	Ščitnica Thyroid gland	M	8	0	0	6	2
		Ž	11	0	0	3	8
C81	Hodgkinov limfom Hodgkin's lymphoma	M	8	0	0	5	3
		Ž	7	0	1	3	3
C82-C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	110	0	0	45	65
		Ž	87	0	1	27	59
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	53	0	2	21	30
		Ž	57	0	0	12	45
C91-C95	Levkemije Leukaemias	M	103	1	4	36	62
		Ž	86	1	2	16	67



Tabela 8: Eno- in pet-letno čisto preživetje (s 95 % intervalom zaupanja) bolnikov po spolu, zbolelih v letih 2016–2020.

Table 8: One- and five-year net survival (with 95% confidence interval) of patients diagnosed in period 2016–2020 by sex.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Eno-letno preživetje s 95 % intervalom zaupanja		Pet-letno preživetje s 95 % intervalom zaupanja	
			One-year survival with 95% confidence interval		Five-year survival with 95% confidence interval	
C00–C96 brez C44**	Vse lokacije All sites	M+Ž	75,7	75,3–76,0	59,9	59,3–60,4
		M	74,2	73,7–74,7	58,0	57,3–58,7
		Ž	77,4	76,9–77,9	62,0	61,3–62,8
C00–C14	Usta in žrelo Mouth and pharynx	M	73,5	71,0–76,1	45,1	41,7–48,6
		Ž	84,8	81,1–88,7	63,5	57,4–70,1
C15	Požiralnik Oesophagus	M	35,4	30,7–40,7	12,1	8,8–16,6
		Ž	34,7	26,1–46,1	15,2	9,0–25,7
C16	Želodec Stomach	M	52,9	50,1–55,8	29,3	26,3–32,7
		Ž	51,6	48,1–55,3	31,2	27,6–35,2
C18	Debelo črevo Colon	M	79,6	77,8–81,4	63,0	60,2–66,1
		Ž	80,0	78,0–82,0	63,2	60,1–66,5
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	84,1	82,1–86,1	63,4	60,0–66,9
		Ž	80,2	77,5–83,1	59,3	55,3–63,7
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	36,1	33,0–39,6	11,1	8,8–13,9
		Ž	29,8	25,2–35,3	11,0	7,7–15,9
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	37,3	33,2–42,0	13,5	10,4–17,6
		Ž	28,4	24,6–32,9	10,7	7,9–14,5
C25	Trebušna slinavka Pancreas	M	31,5	28,8–34,5	9,3	7,4–11,6
		Ž	28,8	26,0–31,8	9,1	7,3–11,4
C32	Grlo Larynx	M	88,0	84,8–91,4	66,5	60,6–73
		Ž	*		*	
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	46,6	45,2–48,1	20,4	19,0–21,8
		Ž	55,1	53,2–56,9	28,3	26,4–30,2
C43	Maligni melanom kože Malignant melanoma of skin	M	96,6	95,3–97,9	87,3	84,1–90,7
		Ž	98,3	97,3–99,4	92,4	89,5–95,3
C44	Druge maligne neoplazme kože Skin, excl. melanoma	M	**		**	
		Ž	**		**	
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	78,3	72,2–84,9	54,9	46,6–64,6
		Ž	80,1	74,6–86,1	53,0	44,8–62,6
C50	Dojka Breast	M	*		*	
		Ž	96,8	96,2–97,3	87,6	86,3–88,9
C53	Maternični vrat Cervix uteri	M	–		–	
		Ž	84,8	81,7–88,0	72,4	68,1–77
C54	Maternično telo Corpus uteri	M	–		–	
		Ž	91,7	90,3–93,1	79,3	76,7–82,1
C56	Jajčnik Ovary	M	–		–	
		Ž	75,5	72,4–78,8	47,2	43,2–51,5
C61	Prostata Prostate	M	97,8	97,3–98,3	94,0	92,7–95,3
		Ž	–		–	
C62	Modo Testis	M	99,1	98,3–100,0	97,1	95,3–99,0
		Ž	–		–	
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	82,2	80,0–84,4	70,8	67,5–74,3
		Ž	75,0	71,6–78,5	61,5	56,6–66,9
C67	Sečni mehur Bladder	M	77,0	74,5–79,6	55,0	51,1–59,3
		Ž	65,6	61,3–70,2	49,2	43,8–55,3
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	48,2	44,0–52,8	20,2	16,8–24,3
		Ž	44,7	39,8–50,2	16,7	12,9–21,5
C73	Ščitnica Thyroid gland	M	95,7	92,8–98,7	87,6	79,6–96,5
		Ž	97,0	95,7–98,4	97,0	94,8–99,2
C81	Hodgkinov limfom Hodgkin's lymphoma	M	91,9	87,2–96,8	85,0	78,3–92,2
		Ž	91,3	86,4–96,4	85,8	78,8–93,5
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	76,9	74,3–79,6	65,1	61,4–69,0
		Ž	79,8	77,3–82,3	68,0	64,4–71,9
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	M	81,6	77,6–85,7	53,0	46,9–59,9
		Ž	79,3	74,9–84,0	49,6	43,0–57,1
C91–C95	Levkemije Leukaemias	M	75,4	72,6–78,2	60,3	56,5–64,4
		Ž	71,5	68,4–74,9	55,1	50,7–60,0

\* Število v analizo vključenih bolnikov je v povprečju manjše od 15 na leto / Average number of patients included in the analysis is less than 15 annually

\*\* Preživetje bolnikov z nemelanomskim kožnim rakom se ne razlikuje v primerjavi s splošno populacijo

Survival of patients with non-melanoma skin cancer does not differ in comparison with the general population

Tabela 9a: Število in deleži bolnikov (brez primerov, registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2020, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemskim zdravljenjem ali obsevani (številka v oklepaju se nanaša na obsevane na Onkološkem inštitutu Ljubljana - OIL).

Table 9a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by surgery, systemic therapy or radiotherapy during their first treatment (in parenthesis the number of radiotherapies at Institute of Oncology Ljubljana - IOL is given).

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število kakorkoli zdravljenih* Number of all treated*		Število operiranih Number of treated by surgery		Število zdravljenih s sistemsko terapijo No. of treated by systemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%**	Število Number	%**	Število Number	%**	Število (od tega OIL) Number (IOL only)	%**
C00-C96	Vse lokacije / All sites	15062	12206	81,0	9365	62,2	4439	29,5	3138 (2691)	20,8
C00-C14	Usta in žrelo Mouth and pharynx	326	290	89,0	157	48,2	19	5,8	218 (217)	66,9
C15	Požiralnik Oesophagus	94	49	52,1	13	-	16	17,0	34 (30)	36,2
C16	Želodec Stomach	423	260	61,5	186	44,0	120	28,4	41 (25)	9,7
C18	Debelo črevo Colon	821	702	85,5	665	81,0	199	24,2	10 (7)	-
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	478	396	82,8	312	65,3	168	35,1	173 (168)	36,2
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	234	90	38,5	35	15,0	49	20,9	7 (4)	-
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	198	85	42,9	66	33,3	40	20,2	7 (7)	-
C25	Trebušna slinavka Pancreas	419	188	44,9	98	23,4	128	30,5	12 (11)	-
C32	Grlo Larynx	91	82	90,1	47	51,6	5	-	66 (66)	72,5
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1553	1078	69,4	420	27,0	476	30,7	480 (411)	30,9
C43	Maligni melanom kože Malignant melanoma of skin	639	635	99,4	632	98,9	41	6,4	31 (31)	4,9
C44	Druge maligne neoplazme kože Skin, excl. melanoma	3008	2960	98,4	2841	94,4	26	0,9	122 (122)	4,1
C48-C49	Vezivno in mehko tkivo Connective and soft tissue	87	79	90,8	57	65,5	20	23,0	35 (35)	40,2
C50	Dojka Breast	1455	1399	96,2	1223	84,1	1331	91,5	976 (720)	67,1
C53	Maternični vrat Cervix uteri	133	121	91,0	96	72,2	14	-	72 (66)	54,1
C54	Maternično telo Corpus uteri	373	347	93,0	332	89,0	69	18,5	131 (121)	35,1
C56	Jajčnik Ovary	151	119	78,8	107	70,9	94	62,3	1 (0)	-
C61	Prostata Prostate	1452	1078	74,2	726	50,0	399	27,5	174 (148)	12,0
C62	Modo Testis	112	112	100	112	100,0	67	59,8	0 (0)	-
C64-C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	415	325	78,3	282	68,0	49	11,8	19 (17)	4,6
C67	Sečni mehur Bladder	384	349	90,9	342	89,1	63	16,4	24 (20)	6,3
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	184	150	81,5	140	76,1	80	43,5	110 (106)	59,8
C73	Ščitnica Thyroid gland	175	167	95,4	162	92,6	162	92,6	102 (101)	58,3
C81	Hodgkinov limfom Hodgkin's lymphoma	47	43	91,5	2	-	41	87,2	10 (10)	-
C82-C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	460	340	73,9	38	8,3	269	58,5	121 (118)	26,3
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	155	134	86,5	2	-	129	83,2	18 (12)	11,6
C91-C95	Levkemije Leukaemias	365	181	49,6	1	-	174	47,7	12 (12)	-

\* Število bolnikov zdravljenih s specifičnim onkološkim zdravljenjem v okviru prvega zdravljenja ne glede na način zdravljenja (vključno z drugimi zdravljenji, ki ne spadajo med operacijo, sistemsko terapijo ali obsevanje)

Number of all treated patients with specific oncological treatment regardless of the means of treatment (including other treatments not included into surgery, systemic therapy or radiotherapy)

\*\* Odstotki niso računani, če je število zdravljenih manjše od 15

Percentages are not calculated for less than 15 cases

Tabela 9b:

Število bolnikov (brez primerov, registriranih samo iz zdravniških poročil o vzroku smrti) v Sloveniji, zbolelih leta 2020, ki so bili v okviru prvega zdravljenja operirani\*, po ustanovi posega.

Table 9b:

Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by surgery during their first treatment\* by treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splšna bolnišnica Brežice	Splšna bolnišnica Celje	Splšna bolnišnica Jesenice	Splšna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splšna bolnišnica Murska Sobota	Splšna bolnišnica Nova Gorica	Splšna bolnišnica Novo mesto	Splšna bolnišnica Ptuj	Splšna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00-C96	Vse lokacije All sites	15062	9365	30	668	294	242	2313	1352	1771	319	203	437	119	426	1018	173
C00-C14	Usta in žrelo Mouth and pharynx	326	157	0	2	1	1	119	1	29	1	1	2	0	0	0	0
C15	Požiralnik Oesophagus	94	13	0	0	0	0	11	0	1	0	0	0	0	0	1	0
C16	Želodec Stomach	423	186	0	6	7	9	81	12	56	7	1	1	1	0	4	1
C18	Debelo črevo Colon	821	665	8	48	61	46	187	61	75	29	32	29	17	28	27	17
C19-C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	478	312	3	12	11	29	74	77	35	7	4	11	5	17	23	4
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	234	35	0	0	0	0	20	1	13	0	0	0	1	0	0	0
C23-C24	Žolčnik in žolčevodi Gallbladder and biliary tract	198	66	1	2	2	1	38	0	16	2	0	1	1	2	0	0
C25	Trebušna slinavka Pancreas	419	98	0	0	0	5	60	1	31	0	0	0	0	0	0	1
C32	Grla Larynx	91	47	0	3	0	0	27	0	17	0	0	0	0	0	0	0
C33-C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1553	420	0	2	0	0	127	1	94	0	0	0	0	0	194	2
C43	Malignni melanom kože Malignant melanoma of skin	639	632	3	68	32	28	128	41	66	12	15	34	13	9	144	39
C44	Druge maligne neoplazme kože Skin, excl. melanoma	3008	2841	10	305	125	85	490	30	635	173	24	252	75	24	556	57
C48-C49	Veživno in mehko tkivo Connective and soft tissue	87	57	1	0	0	0	12	37	5	0	0	1	1	0	0	0
C50	Dojka Breast	1455	1223	0	28	0	0	1	819	296	1	48	0	0	25	1	4
C53	Maternični vrat Cervix uteri	133	96	2	3	1	2	60	3	11	2	0	0	2	1	0	9
C54	Maternično telo Corpus uteri	373	332	1	16	14	8	139	49	56	9	10	11	0	4	0	15
C56	Jajčnik Ovary	151	107	1	2	2	3	49	24	13	0	4	2	1	4	0	2
C61	Prostata Prostate	1452	726	0	106	16	5	154	3	88	32	29	27	0	216	47	3
C62	Modo Testis	112	112	0	10	1	1	54	0	19	6	5	7	0	8	0	1
C64-C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	415	282	0	15	1	1	90	13	55	14	13	26	0	46	3	5
C67	Sečni mehur Bladder	384	342	0	26	13	15	141	0	53	15	12	26	0	36	1	4
C70-C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	184	140	0	2	0	0	87	0	51	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	175	162	0	4	0	0	18	120	13	0	0	0	0	0	6	1
C81	Hodgkinov limfom Hodgkin's lymphoma	47	2	0	0	0	0	2	0	0	0	0	0	0	0	0	0
C82-C85	ne-Hodgkinovi limfomi non-Hodgkin's lymphoma	460	38	0	1	2	0	12	12	5	1	1	1	0	1	2	0
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	155	2	0	1	0	0	0	0	0	0	0	0	0	1	0	0
C91-C95	Levkemije Leukaemias	365	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0

\* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

Patients that underwent multiple surgery procedures in the course of first treatment were included with the first procedure only

\*\* V posamezni ustanovi so operirali manj kot 30 bolnikov

Less than 30 patients were treated by surgery in individual institution

Tabela 9c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) v Sloveniji, zbolelih leta 2020, ki so v okviru prvega zdravljenja prejeli sistemsko zdravljenje\*, po ustanovi zdravljenja.  
 Table 9c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2020, that were treated by systemic therapy during their first treatment\* by treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemsko terapijo Number of treated systemic therapy	Splošna bolnišnica Celje	Univerzitetna klinika Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	15062	4439	71	141	28	460	2548	876	38	92	55	77	22	18
C00–C14	Usta in žrelo Mouth and pharynx	326	19	0	0	0	0	18	0	0	0	1	0	0	0
C15	Požiralnik Oesophagus	94	16	0	0	0	0	10	6	0	0	0	0	0	0
C16	Želodec Stomach	423	120	0	0	0	6	60	52	0	1	0	1	0	0
C18	Debelo črevo Colon	821	199	0	0	0	1	137	54	1	2	0	4	0	0
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	478	168	0	0	0	1	153	12	0	1	0	1	0	0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	234	49	0	0	0	33	4	11	0	0	1	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	198	40	0	0	0	17	10	13	0	0	0	0	0	0
C25	Trebušna slinavka Pancreas	419	128	0	0	0	37	42	42	0	5	0	1	0	0
C32	Grlo Larynx	91	5	0	0	0	0	5	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1553	476	0	131	0	0	219	124	0	0	0	0	0	0
C43	Maligni melanom kože Malignant melanoma of skin	639	41	0	0	0	0	41	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, excl. melanoma	3008	26	1	0	0	2	7	13	0	0	1	0	1	1
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	87	20	0	0	0	4	16	0	0	0	0	0	0	0
C50	Dojka Breast	1455	1331	16	0	5	0	890	346	0	46	2	19	1	1
C53	Maternični vrat Cervix uteri	133	14	0	0	0	0	11	3	0	0	0	0	0	0
C54	Maternično telo Corpus uteri	373	69	0	0	0	0	56	13	0	0	0	0	0	0
C56	Jajčnik Ovary	151	94	0	0	0	1	74	18	0	1	0	0	0	0
C61	Prostata Prostate	1452	399	26	0	13	73	97	55	17	23	39	32	14	9
C62	Modo Testis	112	67	0	0	0	1	66	0	0	0	0	0	0	0
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	415	49	0	0	0	2	33	14	0	0	0	0	0	0
C67	Sečni mehur Bladder	384	63	0	0	0	3	46	8	5	0	0	1	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	184	80	0	0	0	9	71	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	175	162	4	0	0	15	123	13	0	0	0	0	6	0
C81	Hodgkinov limfom Hodgkin's lymphoma	47	41	0	0	0	3	38	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	460	269	4	0	2	20	229	6	1	1	1	2	0	1
C90	Difuzni plazmocitom in maligne neoplazme plazmatk Multiple myeloma and malignant plasma cell neoplasms	155	129	6	0	4	67	0	20	9	6	5	8	0	4
C91–C95	Levkemije Leukaemias	365	174	10	0	3	110	8	24	3	5	4	7	0	0

\* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat  
 Patients that underwent multiple systemic treatments in the course of first treatment were included with the first treatment only

\*\* V posamezni ustanovi so zdravili manj kot 10 bolnikov  
 Less than 10 patients were treated in individual institution

# Breme najpogostejših rakov


## Cancer Fact Sheets

### Vsi raki / All cancer sites (C00–C96)


INCIDENCA (povprečje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	8400	7346	15746
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	37,6	30,1	33,7
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	810,9	705,0	757,8
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	396,4	318,9	350,9
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	1,0	2,4*	1,7*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-1,0*	1,4*	0,1
UMRLJIVOST (povprečje v obdobju 2016–2020) / MORTALITY (average during 2016–2020)			
Število smrti v enem letu / Number of deaths per year	3562	2812	6374
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	14,9	9,3	12,0
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	343,8	269,9	306,8
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	148,8	89,8	115,4
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	0,8*	1,2*	1,0*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-1,7*	-0,8	-1,2*
PREVALENCA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020)			
Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence)	57593	67237	124830
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020	5461,7	6430,2	5943,9
Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis	6386	5837	12223
Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis	20078	19709	39787

\* Statistično značilno / Statistically significant

#### Incidenca Incidence Slovenija 1961–2020



#### Umrljivost Mortality Slovenija 1985–2020




# Prostata / Prostate (C61)


INCIDENCA (povprečje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020)	Moški / Male
Število novih primerov v enem letu / Number of new cases per year	1648
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	19,6
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	2.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	24,5
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	9,8
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	159,2
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	74,6
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	-0,6
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-2,8*
UMRLJIVOST (povprečje v obdobju 2016–2020) / MORTALITY (average during 2016–2020)	
Število smrti v enem letu / Number of deaths per year	445
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	12,5
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	1,2
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	42,9
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	15,3
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	2,2*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-0,9
PREVALENCIA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020)	
Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence)	16607
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020	1574,9
Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis	1358
Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis	5692

\* Statistično značilno / Statistically significant

## Incidenca Incidence Slovenija 1961–2020



## Umrljivost Mortality Slovenija 1985–2020




# Pljuča in sapnik / Lung and trachea (C33, C34)


INCIDENCA (povprečje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	968	595	1563
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	11,5	8,1	9,9
Mesto po pogostosti med vsemi raki / Frequency rank among all cancers	3.	3.	3.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	14,4	10,5	12,6
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	5,7	3,2	4,4
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	93,5	57,1	75,3
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	44,7	24,8	33,9
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	1,3	6,3*	3,1*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-0,8	4,4*	1,1*
UMRLJIVOST (povprečje v obdobju 2016–2020) / MORTALITY (average during 2016–2020)			
Število smrti v enem letu / Number of deaths per year	776	438	1214
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	21,8	15,6	19,0
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	4,27	2,1	3,1
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	74,9	42,1	58,4
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	34,4	16,3	24,6
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-0,7	3,9*	0,9*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-2,9*	1,7	-1,3*
PREVALENCIA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020)			
Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence)	2441	1805	4246
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020	231,5	172,6	202,2
Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis	572	423	995
Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis	1008	819	1827

\* Statistično značilno / Statistically significant

## Incidenca Incidence Slovenija 1961–2020



## Umrljivost Mortality Slovenija 1985–2020




# Dojka / Breast (C50)


INCIDENCA (povprečje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020)	Ženske / Female
Število novih primerov v enem letu / Number of new cases per year	1481
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	20,2
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	2.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	26,1
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	8,1
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	142,2
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	74,6
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	2,6*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	1,8*
UMRLJIVOST (povprečje v obdobju 2016–2020) / MORTALITY (average during 2016–2020)	
Število smrti v enem letu / Number of deaths per year	439
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	15,6
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	1,5
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	42,2
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	14,6
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	1,8*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-0,1
PREVALENCIA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020)	
Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence)	19833
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020	1896,7
Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis	1384
Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis	5157

\* Statistično značilno / Statistically significant

## Incidenca Incidence Slovenija 1961–2020



## Umrlijivost Mortality Slovenija 1985–2020






# Debelo črevo in danka / Colon and rectum (C18–C20)


INCIDENCA (povprečje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	814	561	1375
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	9,7	7,6	8,7
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	4.	4.	5.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	12,1	9,9	11,1
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	4,2	2,5	3,3
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	78,5	53,8	66,2
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	37,0	21,4	28,4
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	-2,5*	-1,6*	-2,1*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-4,5*	-2,7*	-3,8*
UMRLJIVOST (povprečje v obdobju 2016–2020) / MORTALITY (average during 2016–2020)			
Število smrti v enem letu / Number of deaths per year	421	297	718
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	11,8	10,6	11,2
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	1,7	0,8	1,2
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	40,6	28,5	34,5
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	16,8	8,2	12,0
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-1	-2,5*	-1,6*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-3,8*	-4,4*	-3,9*
PREVALENCIA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020)			
Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence)	6961	5374	12335
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020	660,1	513,9	587,3
Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis	644	431	1075
Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis	2000	1395	3395

\* Statistično značilno / Statistically significant

## Incidenca Incidence Slovenija 1961–2020



## Umrljivost Mortality Slovenija 1985–2020




# Koža, razen melanoma / Skin, non-melanoma (C44)


INCIDENCA (povprečje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	1662	1664	3326
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	19,8	22,7	21,1
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	1.	1.	1.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	/	/	/
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	7,6	6,6	7,1
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	160,4	159,7	160,4
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	72,5	62,2	65,9
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	4,1*	4,5*	4,3*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	1,6	3,6*	2,6*
UMRLJIVOST (povprečje v obdobju 2016–2020) / MORTALITY (average during 2016–2020)			
Število smrti v enem letu / Number of deaths per year	24	27	51
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	0,7	1,0	0,8
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	0,05	0,01	0,03
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	2,3	2,6	2,5
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	0,8	0,5	0,6
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-	-	-
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-	-	-
PREVALENCIA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020)			
Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence)	16857	18386	35243
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020	1598,6	1758,3	1678,1
Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis	1521	1401	2922
Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis	5806	6141	11947

\* Statistično značilno / Statistically significant

## Incidenca Incidence Slovenija 1961–2020



## Umrljivost Mortality Slovenija 1985–2020




# Kožni melanom / Malignant melanoma of skin (C43)


INCIDENCA (povprečje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	316	294	610
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	3,8	4,0	3,9
Mesto po pogostosti med vsemi raki / Frequency rank among all cancers	6.	6.	6.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	4,7	5,2	4,9
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	1,8	1,6	1,7
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	30,5	28,3	29,4
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	16,3	15,9	15,8
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	2,2*	2,8*	2,5*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	0,1	1,5	0,8
UMRLJIVOST (povprečje v obdobju 2016–2020) / MORTALITY (average during 2016–2020)			
Število smrti v enem letu / Number of deaths per year	70	55	125
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	2,0	2,0	2,0
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	0,4	0,2	0,3
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	6,7	5,3	6,0
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	3,2	2,0	2,5
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-0,6	0,7	0,1
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-3,2	-2,2	-2,8*
PREVALENCIA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020)			
Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence)	3534	4230	7764
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020	335,1	404,5	369,7
Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis	318	299	617
Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis	1024	1029	2053

\* Statistično značilno / Statistically significant

## Incidenca Incidence Slovenija 1961–2020



## Umrlijivost Mortality Slovenija 1985–2020




# Glava in vrat / Head and neck (C00–C14, C30–C32)


INCIDENCA (povprečje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	362	103	465
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	4,3	1,4	3,0
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	5.	15.	7.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	5,4	1,8	3,7
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	2,3	0,6	1,4
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	34,9	9,9	22,4
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	18,7	4,9	11,6
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	-0,8	0,7	-0,4
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-2,4*	-0,7	-2,0*
UMRLJIVOST (povprečje v obdobju 2016–2020) / MORTALITY (average during 2016–2020)			
Število smrti v enem letu / Number of deaths per year	173	36	209
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	4,8	1,3	3,3
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	1,05	0,17	0,6
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	16,7	3,5	10,1
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	8,4	1,4	4,7
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	-1,9	-0,4	-1,5
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	-3,8*	-3,5	-3,4*
PREVALENCIA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020)			
Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence)	2703	959	3662
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020	256,3	91,7	174,4
Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis	284	84	368
Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis	823	276	1099

\* Statistično značilno / Statistically significant

## Incidenca Incidence Slovenija 1961–2020



## Umrljivost Mortality Slovenija 1985–2020




# Maternično telo / Corpus uteri (C54)


INCIDENCA (povprečje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020)	Ženske / Female
Število novih primerov v enem letu / Number of new cases per year	367
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	5,0
Mesto po pogostnosti med vsemi raki / Frequency rank among all cancers	5.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	6,5
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	2,0
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	35,2
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	16,4
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	2,1*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	1,2
UMRLJIVOST (povprečje v obdobju 2016–2020) / MORTALITY (average during 2016–2020)	
Število smrti v enem letu / Number of deaths per year	71
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	2,5
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	0,26
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	6,8
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	2,2
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	6,0*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	5,8*
PREVALENCIA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020)	
Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence)	5049
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020	482,9
Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis	346
Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis	1142

\* Statistično značilno / Statistically significant

## Incidenca Incidence Slovenija 1961–2020



## Umrlijivost Mortality Slovenija 1985–2020




# Ne-Hodgkinov limfom / Non-Hodgkin's lymphoma (C82–C85)


INCIDENCA (povprečje v obdobju 2016–2020) / INCIDENCE (average during 2016–2020)	Moški / Male	Ženske / Female	Skupaj / All
Število novih primerov v enem letu / Number of new cases per year	231	223	454
Odstotek med vsemi raki (%) / Percentage of all cancers (%)	2,8	3,0	2,9
Mesto po pogostosti med vsemi raki / Frequency rank among all cancers	10.	7.	8.
Odstotek med vsemi raki razen kožnega (%) / Percentage of all cancers excl. non-melanoma skin (%)	3,4	3,9	3,7
Tveganje raka do 75. leta starosti (%) / Risk of getting cancer before age 75 (%)	1,3	1,1	1,2
Groba incidenčna stopnja na 100.000 / Crude incidence rate per 100,000	22,3	21,4	21,9
Starostno standardizirana incidenčna stopnja (SSS) na 100.000 / Age-standardized incidence rate (ASR) per 100,000	11,8	9,5	10,5
Ocenjeni delež letne spremembe grobe inc. stopnje zadnjih 10 let (%) / Estimated annual change of crude incidence rate latest 10 years (%)	2,6*	2,4*	2,5*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	0,9	1,5	1,3
UMRLJIVOST (povprečje v obdobju 2016–2020) / MORTALITY (average during 2016–2020)			
Število smrti v enem letu / Number of deaths per year	96	86	182
Odstotek med vsemi smrtmi zaradi raka (%) / Percentage of all cancer deaths (%)	2,7	3,1	2,9
Tveganje smrti za rakom do 75. leta starosti (%) / Risk of dying from cancer before age 75 (%)	0,4	0,3	0,3
Groba umrljivostna stopnja na 100.000 / Crude mortality rate per 100,000	9,3	8,3	8,8
Starostno standardizirana umrljivostna stopnja (SSS) na 100.000 / Age-standardized mortality rate (ASR) per 100,000	3,8	2,4	3,0
Ocenjeni delež letne spremembe grobe umr. stopnje zadnjih 10 let (%) / Estimated annual change of crude mortality rate latest 10 years (%)	6,1*	2,0	4,1*
Ocenjeni delež letne spremembe SSS zadnjih 10 let (%) / Estimated annual change of ASR latest 10 years (%)	2,9	0,4	1,7
PREVALENCIA (na dan 31.12.2020) / PREVALENCE (on December 31, 2020)			
Število živih oseb z diagnozo raka ob koncu leta 2020 (prevalenca) / Persons living with cancer at the end of 2020 (prevalence)	1888	1947	3835
Število živih oseb z diagnozo raka na 100.000 (prevalenčna stopnja) / Number of persons living with cancer per 100,000 at the end of 2020	179,0	186,2	182,6
Število živih oseb z diagnozo raka manj kot eno leto po diagnozi / Persons living with cancer less than 1 year after diagnosis	186	184	370
Število živih oseb z diagnozo raka 1–4 leta po diagnozi / Persons living with cancer 1-4 years after diagnosis	581	598	1179

\* Statistično značilno / Statistically significant

## Incidenca Incidence Slovenija 1961–2020



## Umrljivost Mortality Slovenija 1985–2020



Definicije kazalnikov in metod so podrobneje razložene na spletnem portalu SLORA:  
<http://www.slora.si/definicije-kazalnikov-in-metod>.

- Incidenca** Število vseh na novo ugotovljenih primerov raka v točno določeni populaciji v enem koledarskem letu.
- Umrljivost** Število vseh umrlih za določeno boleznijo v točno določeni populaciji v enem koledarskem letu.
- Prevalenca** Število vseh bolnikov z določeno boleznijo, ki so bili živi na izbrani datum (ponavadi zadnji dan v letu). Glede na čas, kdaj so zboleli, ločimo:
- Celotna prevalenca upošteva vse bolnike z rakom ne glede na to, kdaj so zboleli.
  - Delna prevalenca upošteva tiste bolnike z rakom, ki so zboleli v točno določenem obdobju pred datumom izračuna. Na primer, v enoletno delno prevalenco so vključeni bolniki, ki so zboleli leto dni pred datumom izračuna ter so na ta datum še živi.
- Preživetje** Preživetje predstavlja delež bolnikov, ki so po izbranem obdobju od postavitve diagnoze še živi. V poročilu podajamo čisto preživetje, izračunano po metodi Pohar-Perme, ki ocenjuje preživetje bolnikov v primeru, da bi upoštevali kot vzrok smrti samo proučevanega raka (hipotetičen primer, v katerem ne umirajo zaradi drugih vzrokov smrti).
- Groba stopnja** Incidenca ali umrljivost, preračunani na velikost opazovane populacije. Običajno je izražena na 100.000 prebivalcev.
- Starostno standardizirana stopnja** Starostna standardizacija nam pove, kakšna bi bila groba stopnja v opazovani populaciji, če bi bila starostna struktura te populacije enaka kot je v standardni populaciji. Uporabljene so tri standardne populacije: svetovna (Segi 1961), evropska (Doll 1976) in slovenska standardna populacija (Popis 2002).
- Kumulativna stopnja** Kumulativna incidenčna ali umrljivostna stopnja je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativna stopnja je približek za kumulativno tveganje.
- Kumulativno tveganje** Kumulativno tveganje izražamo v odstotkih in interpretiramo kot verjetnost posameznika, da zboli za rakom v izbranem starostnem obdobju (npr. do svojega 74. leta starosti), če ne umre prej zaradi drugih vzrokov.
- Ocena incidence** Ocena števila novih primerov za tekoče koledarsko leto 2020 je pripravljena z metodo po Dybi in Hakulinenu. V model so vključeni bolniki glede na obdobje diagnoze in starost ob diagnozi za zadnjih deset let, ko so podatki na voljo.

Definitions of indicators and methods are explained in detail on web portal SLORA:  
<http://www.slora.si/en/definicije-kazalnikov-in-metod>.

**Incidence** Number of all newly diagnosed cancer cases that develop in a defined population in one calendar year.

**Mortality** Number of all patients who died because of certain disease in a defined population in one calendar year.

**Prevalence** Prevalence is the number of all patients with specific disease that are alive on a given date (usually the last day of the year). According to the time of diagnosis we distinguish:

- Lifetime prevalence is defined as the number of all persons ever diagnosed with cancer and being alive at a specific time date.
- Partial prevalence is the number of only those cancer patients, who were diagnosed with cancer within a defined period of time before the date of calculation. For example, one year partial prevalence includes patients diagnosed with cancer one year before the date of calculation.

**Survival** In groups of patients, survival represents the proportion of patients still alive after a selected period of time from diagnosis. The net survival calculated by Pohar-Perme method is given. It estimates patients' survival from cancer only (all other causes of death excluded).

**Crude rate** Incidence or mortality calculated per observed population, usually expressed per 100.000 population.

**Age-standardized rate** Age-standardization tells what the crude rate would be in observed population, if its age structure were the same as in standard population. For comparison we used three standard populations: World (Segi 1961), European (Doll 1976) and Slovenian standard population (Census 2002).

**Cumulative rate** The cumulative incidence or mortality rate is a special form of direct age standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. Cumulative rate is an approximation for the cumulative risk.

**Cumulative risk** Cumulative risk is expressed in percentages and interpreted as the risk an individual would have of developing the disease in question during a certain age range (e.g. up to the age of 74), if there were no other causes of death.

**Estimation of incidence** Estimation of cancer cases in present calendar year 2020 is calculated by the Dyba and Hakulinen method. This model includes patients according to the period of diagnosis and their age at diagnosis for the last ten registered years.



